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The major aim of the work presented in this thesis relates to site-specific drug delivery of 
peptide analogues. A model system was used to study the binding and subsequent uptake 
of a-MSH analogues into B16 murine melanoma cells by receptor-mediated endocytosis. 
An acid wash technique was introduced to differentiate between extracellularly bound and 
internalised ligand. An additional area of work was the fate of the ligands once they were 
inside the cells.
The superpotent a-MSH analogue, Ac-[Nle4,D-Phe7] a-MSH, was labelled with 125I and 
bound to B16 murine melanoma cells. At 4°C, no internalisation of the ligand was 
observed. However, at 37°C, the 1251 activity appeared to increase steadily until 30 
minutes, after which time a gradual decrease in internalised ligand was seen to occur. 
Inclusion of the exogenous amine, ammonium chloride, into the experimental set-up, 
caused the 125I activity to continue increasing throughout the entire timecourse of the 
experiment. No decrease was observed after 30 minutes as before. This implied that 
lysosomal degradation may have been the reason for the decrease.
Sucrose gradient fractionation techniques were used to observe the fate of the ligand after 
internalisation, the rationale being that the various components in the cells would separate 
out at different densities of sucrose when subjected to a centrifugation step in a linear 
sucrose gradient. These experiments further indicated that once internalised the ligands 
made their way to the lysosomal compartment. This was determined from the observation 
of increased 125I activity in denser fractions of the sucrose gradient known to be 
associated with the lysosome.
Larger a-MSH analogues were also prepared, iodinated and their binding and 
internalisation studied in the B16 murine melanoma cell system. As for 125I-[Tyr2,Nle4,D- 
Phe7] a-MSH, ammonium chloride was tested in the system. Overall, the larger the ligand, 
the slower the rate of internalisation.
Overall, the results reported in this thesis strongly favour the concept that a-MSH 
analogues are internalised into B16 murine melanoma cells via receptor-mediated 
endocytosis. Moreover, once inside, they make their way to the lysosomal compartment 
where degradation may occur.
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1.1 The Rationale Behind the Concept of Drug Targeting
The selective delivery of chemotherapeutic agents to their site of action should increase 
therapeutic effectiveness and limit side effects. The clinical use of a therapeutic agent can 
only be justified if its beneficial effects outweigh its toxic effects (Sezaki, H.; 1984). Most 
drug therapies currently available, however, exhibit little, if any site specificity. Many times 
a drug has limited or no access to its intended site of action or is prematurely metabolised 
or excreted. In other instances, the drug travels rather freely throughout the body and not 
only acts on the desired target tissues but also causes undesirable effects on non-target 
tissues (Friend, D.R.; 1987). Most medications are, thus, associated to some degree with 
toxic side effects. This principle is best illustrated by the use of chemotherapeutic agents in 
the treatment of cancer where inhibition of tumour growth is invariably accompanied by 
serious toxicity to rapidly proliferating normal cells. Hence, the need for effective drug 
delivery systems is straightforward. For a drug to produce a specific pharmacological 
response it must gain access to its specific "site of action". In the design of specific drugs 
and drug delivery systems, particular attention must be given to:-
1. The desired site of action of the drug.
2. The route of administration of the drug.
3. The pathway or barriers that the drug must pass en route to its destination.
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Depending on the nature of the drug one must also ask whether there are specific regions 
of the body that the drug must avoid either because it is toxic or because it may be rapidly 
degraded in that region (Pozansky, M.J. & Juliano, R.L.; 1984).
One of the most fundamental barriers to selective drug delivery involves the so called 
"targeting" problem. Much of the intellectual excitement in the drug delivery area revolves 
around the concept of directing therapeutic agents to a particular cell population where 
desirable effects can be achieved without exposing other cell populations where toxic 
effects occur. The most obvious example of this would be a toxic agent that can 
discriminate between neoplastic and non-neoplastic cells. However, many other examples 
related to infectious diseases and genetic disorders come readily to mind (Pozansky, MJ. 
& Juliano, R.L.; 1984).
A number of difficulties are involved in achieving a desired pharmacological (or other) 
response at a selected site without undesired interaction at other sites (Gardner, C.R.; 
1985). If we consider the problem of targeting a cytotoxic agent to neoplastic but not to 
normal cells as an example, the following difficulties may need to be overcome.
First, this approach presumes the existence of something to aim at, that is, some molecular 
characteristic that differs between target and non-target cells. This might be a surface 
receptor, a structural membrane protein, an intracellular enzyme, or an altered sequence in 
the genome. Clearly the first task is to establish that a discrete and accessible molecular 
difference does exist between target and non-target cells. New developments in the 
characterisation of oncogenes and their products of monoclonal and polyclonal antibodies 
to tumour associated antigens strongly suggest that it will be possible to establish distinct 
molecular differences between normal and tumour cells (Eppstein, D.A. & Longenecker, 
J.P.; 1988).
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The second task is to develop a reagent that will show a high degree of selectivity in 
bringing a toxic drug into (or at least to) the neoplastic cell type. This is far from 
straightforward in the in vivo situation due to involvement in complex sets of non-specific 
interactions and redistribution.
finally, one must realise that a neoplastic cell population is not a static entity, but rather a 
protean, ever changing one. Tumours display an amazing ability to escape or neutralise the 
actions of drugs or other therapeutic agents to which they were initially sensitive. Some 
common examples of this are:-
1. The loss of specific receptors.
2. Down regulation of tumour-associated antigens.
3. Shedding of antigens into the body fluids.
Thus targeted drugs which are initially effective may lose their effectiveness as the tumour 
cell population responds to selective pressures (Pozansky, M.J. & Juliano, R.L.; 1984).
Many efforts have been made to increase the specificity of drugs by association or linkage 
of the drug to a carrier (Tomlinson, E.; 1987). One major advantage of this approach is 
that the absorption and distribution of the drug depends on the physio-chemical properties 
of the carrier, not those of the drug. Thus, the distribution of drugs in the body can be 
manipulated by alterations in the physico-chemical properties of the carrier and by the 
choice of carrier.
For the successful delivery of drugs to a specific site via a drug carrier, the design of the 
drug-carrier complex must conform to a multitude of guidelines:-
3
1. It must protect the drug from inactivation during transit while minimising premature 
drug release.
2. It must localise the drug at the site of action, recognise and interact with specific cells 
and enter the cell or cellular compartment
3. It must allow for release of the active drug chemically or enzymically at controlled and 
predictable rates.
4. It must minimise host toxicity and have no adverse side effects.
5. It must be biodegradable, biochemically inert, and nonimmunogenic.
6. It should be easily prepared in a cost-effective, reproducible manner in homogeneous 
yields.
7. It must be chemically and biochemically stable in its dosage form.
No drug carrier complex has been developed that conforms to all these guidelines. Two 
types of targeting have been defined - passive targeting and active targeting. The former is 
a process which utilises the natural (passive) distribution pattern of the drug carrier to 
deliver drugs to specific sites. This often does not lead to selective uptake by the 
appropriate target and hence, active targeting has been more extensively studied. Active 
targeting systems promote selectivity in various ways:- by altering the normal distribution 
of the drug through use of cell receptors or receptor-recognising molecules; by release of 
drug only when exposed to specific micro environments such as changes in pH or 
temperature; or by directing of drug-carrier complexes via magnetic control. 
Macromolecular and cellular or particulate drug carriers that have been investigated or 
proposed for site-specific drug delivery - passive or active - include antibodies (Ghose, T.; 
1983), glycoproteins (Dean, R.T.; 1979), lipoproteins (Gregoriadis, G.; 1979; Weinstein, 
J.N.; 1981), lectins (Shier, W.T.; 1979), hormones (Varga, J.M. & Asato, N.; 1983), cells 
(Zimmermann, U.; 1983), liposomes (Gregoriadis, G.; 1979; Weinstein, J.N.; 1981), DNA 
(Trouet, A. et al; 1979), dextran (Molteni, L.; 1979) and micro- and nanoparticles with or
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without magnetic control (Tomlinson, E. & McVie, J.G.; 1983). Various synthetic 
polymers, such as N-(2-hydroxyypropyl) methyacrylamide copolymers (Duncan, R. et al; 
1983) and polylysines (Arnold, L.J.; 1983), have also been proposed as components of 
site-selective drug delivery systems. In addition to prodrugs and drug-carrier complexes, 
other techniques that have been used to deliver drugs to their site of action include 
localised chemotherapy whereby the drug is administered directly into the target site, and 
the use of implantable fusion pumps (Friend, D.R. & Pangbum, S.; 1987).
Before discussing in more detail different drug carriers, an account of the mechanism of 
entry of macromolecules into cells will first be described.
1.2 Entry of Macromolecules Into Cells - Endocytosis
Macromolecules because of their large size are generally considered to be impermeable to 
cell membranes and consequently unable to cross transport barriers in biological systems. 
By virtue of this impermeability, many macromolecules have been successfully used as 
drug carriers in order to avoid a rapid clearance from the circulation, or to achieve a 
sustained release when implanted in tissues. Macromolecules used in this type of drug 
delivery include naturally occurring biopolymers, for example, dextrans, albumin, nucleic 
acids, and synthetic polymers such as poly(ethyleneglycol). Other macromolecules have a 
strong affinity to cells due to their multiple binding capacity to either charged or 
hydrophobic regions on the cell surface. Furthermore, many of the natural molecules such 
as antibodies and hormones, possess high specificity for binding to selective cells or 
tissues. These properties can be exploited in the design of earner-mediated delivery 
systems that can enhance the absorption or penetration of drugs, particularly, at selective
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sites. Examples of the systems just mentioned, and their use in drug delivery to the present 
day, will be described in detail later.
Due to their impermeability, cellular uptake of macromolecules into mammalian cells 
depends primarily on a process referred to as endocytosis. In endocytosis, exogenous 
macromolecules either present in the fluid phase or bound to the cell surface, are first 
internalised by the cell via the formation of plasma membrane derived vesicles. These 
vesicles can then be processed through various intracellular organelles and in some cases, 
recycled to the plasma membrane.
Endocytosis is an extremely complex process involving routing, sorting, fusion of 
intracellular organelles, modification and recycling of plasma membrane and acidification 
and degradation of internalised ligands. The extent of endocytosis, for example, can 
determine the efficiency of protein delivery into target cells.
The following sections will focus on the relevance of endocytosis in the development of 
drug delivery systems and the diagram on page 7 illustrates the pathway of endocytosis.
Endocytosis refers to the process of internalisation of extracellular particles and fluids by 
plasma-membrane derived vesicles. The process of internalisation of large particles is 
referred to as phagocytosis, and, pinocytosis refers to the internalisation of extracellular 
fluid.
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G o l g i
N u c l e u s
Figure 1.1: A schematic representation of the vesicular pathways of endocytosis. (a) 
Formation of uncoated vesicles from uncoated pits which may fuse with each other before 
reaching the early endosomes (b). Vesicles from the endosomes, or directly from 
invagination of cell membrane, fuse with primary lysosomes to form secondary lysosomes 
(c). Some vesicles recycle back to the cell membrane (d). Coated regions of the membrane 
can give rise to vesicles with or without a clathrin coat (e). these either fuse with early 
endosomes, primary lysosomes, the Golgi complex, or the opposing cell membrane 
(transcytosis). (f) Vesicles from Golgi complex fuse with primary lysosomes. (g) Vesicles 
arising from lysosomes may fuse with the plasma membrane.
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1.2.1 Receptor-Mediated Endocytosis
Less than 10% of total plasma membrane-associated proteins can have specific affinity for 
a variety of molecules. These membrane-associated proteins are considered as receptors, 
and the molecules which specifically bind to these receptors are known as ligands. 
Following binding on the cell surface the resultant ligand-receptor complex may be 
internalised. In many cases, internalisation is essential for their physiologic functions.
Two major pathways of receptor-mediated endocytosis have been found to occur, and a 
brief description will be outlined below:
1. Clathrin-dependent pathway: the formation of ligand-receptor complex is followed 
by concentration in clathrin-coated regions, or coated pits, of the plasma membrane. These 
coated pits invaginate from the plasma membranes and turn into coated vesicles by 
pinching inward from the membrane. The coated vesicles lose their clathrin coats rapidly, 
and, as a result, smooth membrane vesicles and tubules are formed. These early 
endosomes, which carry receptors and ligands, subsequently participate in a sequence of 
intracellular processing and sorting events.
2. Clathrin-independent pathway: this pathway refers to vesicle formation derived from 
the invagination of non-clathrin-coated plasma membrane. It occurs in receptors with a 
low population and at a slow rate of internalisation, when compared to that of clathrin- 
mediated endocytosis described above.
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1.2.2 Non-Receptor Mediated Endocytosis
This type of endocytosis occurs when no receptor is involved in the internalisation of the 
extracellular matter into the cell. It is derived from constant cell membrane internalisation 
and turnover and is usually unsaturable occurring in both clathrin-dependent and clathrin- 
independent pathways. Two types of pathway have been discovered for this non-receptor 
mediated endocytosis:
1. Fluid-phase endocytosis: due to constant turnover of the plasma membrane, small 
droplets of liquid can be enclosed by an invaginated membrane vesicle and then 
internalised, dragging whatever solutes happen to be in the droplet. As expected this is a 
non-saturable process and the majority of internalised contents reach the lysosome where 
they are catabolised.
2. Adsorptive endocytosis: macromolecules which show a net positive charge or strong 
hydrophobicity can be adsorbed readily onto the cell surface, and internalised into the cell 
via membrane invagination eventually going to the lysosome where degradation occurs.
1.2.3 Intracellular Processing of Endocytosed Macromolecules
The intracellular processing of internalised macromolecules involves several compartments 
in the course of a multi-step transport sequence. They are particularly important when 
macromolecules are used as drug carriers and an intracellular or transcellular release of 
active drugs is required for the pharmacological action. In this regard, it is essential to 
identify the biochemical environment along the endocytotic and transcytotic pathway 
which can be utilised for the processing of internalised macromolecules.
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Endosomes
This is the place where receptors internalised from the cell surface are transferred to. This 
system which is extremely pleomorphic morphologically, extends from the peripheral 
cytoplasm, below the plasma membrane to the Golgi area, adjacent to the nucleus. The 
peripheral elements include vacuoles which are often connected to extensive tubular 
cistemae, and it is with these elements that vesicles coming in from the plasma membrane 
fuse. A wide variety of different ligands internalised by receptor-mediated endocytosis 
have been co-localised within the peripheral elements of the endosome, (Willingham, et al, 
1981) and it seems probable, therefore, that these elements represent the first intracellular 
compartment of the endocytic pathway, irrespective of the form of invagination 
responsible for uptake at the plasma membrane.
The rate at which internalised tracers transfer through the peripheral endosome (5 - 20 
minutes) correlates reasonably well with the rate at which recycling receptor populations 
such as LDL and transferrin are processed intracellularly. It is probable therefore, that 
these receptor populations can return directly to the plasma membrane from peripheral 
endosomal elements. The mode of transfer on the return leg of the cycle has not been 
identified, but is presumed to be a vesicular element. The luminal contents of peripheral 
endosomal elements have a low pH (5.0 to 5.5), which is largely maintained by an ATP- 
dependent proton pump located within their limiting membranes. The acid environment 
within the endosome encourages some receptor-ligand complexes to dissociate and the 
ligand is released into the lumen, while the unoccupied receptor is free to recycle to the 
plasma membrane.
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Not all internalised ligand complexes dissociate in the acid environment of the peripheral 
endosome. Those which remain intact in the acidic environment may be routed through 
the cell to new plasma membrane domains and thus achieve a transcellular transfer.
Lysosomes
This is where most ligands taken up by endocytosis are eventually transferred to. It must 
be noted that there is evidence that macromolecular materials taken up non-specifically in 
the fluid phase will reach this degradative compartment but the efficiency of transfer is 
much less than via receptor-mediated endocytosis.
Lysosomes receive internalised ligands from the peripheral endosome and several recent 
studies of living cells filmed in culture suggest that the juxtanuclear concentration probably 
arises largely as a result of endosomal elements migrating inwards from the cell periphery. 
Tracers introduced into the peripheral endosome system gain access to the juxtanuclear 
elements after a lag of 15 minutes or more. (Hopkins, C.R.; 1984). Therefore, most 
internalised physiological ligands in some manner, yet to be determined, gain access to 
lysosomes. Transfer from endosomes to lysosomes only occurs at temperatures above 22,° 
C, demonstrating that it is a discontinuous step and suggesting that some form of 
membrane fusion is required.
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1.2.4 Characteristics of endocytosis important for drug delivery.
As the intricacies of the process of receptor-mediated endocytosis unfolded over the last 
decade, crucial advantages that the process offered to achieve site specific drug delivery 
began to be apparent and exploited. These advantages accrued from:-
1. High affinity of the receptor for ligand permitting effective sequestration of the ligand 
from low concentrations in the medium.
2. Rapid recycling of the appropriate receptor molecules permitting building up of 
relatively high intracellular ligand concentrations.
3. Expression of specific receptors only on certain cell types permitting design of cell type 
specific drug delivery systems.
4. Specificity as to intracellular compartmentalisation of the ligand depending on the 
nature of the receptor-ligand duo.
The knowledge-base in the area of receptor-mediated endocytosis is being applied towards 
the quest for the ideal target drug of the future which should have at least three elements:-
1. An element for specific recognition by the target cell.
2. An element which would elicit the pharmacological action only at the target site.
3. An element designed to facilitate crossing of anatomic barriers to the target cell.
In general, receptor-mediated stratagems for selective drug delivery, of necessity, depend 
on detailed knowledge about the nature of the ligand, relative distribution of the receptor 
on various cell types, and the intracellular pathways followed by the receptor-ligand 
complexes. As a general rule, efficient drug delivery would be possible only through
12
receptor systems that are recycled rapidly and participate in multiple rounds of drug 
delivery.
1.3 Controlled Drug Delivery
Now an attempt will be made to critically evaluate a range of different drug carrier 
systems including lipid structures such as liposomes, denatured albumin microspheres, 
plasma proteins such as low density lipoproteins and synthetic macromolecules. No 
attempt will be made to include all drug delivery systems available at present. In addition 
both systems which have yielded positive results and those where less encouraging data 
has been obtained will be discussed.
1.3.1 Liposomal Drug Delivery
Liposomes, also known as phospholipid vesicles, have been one of the most popular 
experimental approaches to controlled drug delivery. Several reviews have been published 
on this topic including those by Weinstein, J.N.; (1981), but, a brief summary of their 
chemical and physical characteristics will be included here.
Liposomes are discrete artificial vesicles composed of one or more concentric lipid 
bilayers enclosing an equal number of aqueous spaces. They range in size from 0.02pm to 
100pm. Due to the fact that liposomes can hold drugs within their aqueous spaces, thus 
protecting the drug from the bioenvironment, they are heralded as the ultimate drug carrier 
(Friend, D.R. & Pangbum, S.; 1987). However, physical limitations greatly hinder their 
usefulness in site-specific drug delivery in vitro. This is mainly due to their size, an
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intravenous load of liposomes is taken up to a large degree by phagocytes of the liver and 
spleen (Gregoridias,G.; 1979). Other problems include:-
1. They cannot easily leave the circulation to reach extravascular targets due to size 
effects.
2. Leakage of liposomal contents prior to reaching the target also has been reported.
3. Controlling release of the drug once the liposome reaches the target has proved difficult 
(Juliano,K.L.; 1982).
The major reason why liposomes have been less successful than originally hoped is the fact 
that cell fusion appears to be the primary method of introducing liposomal contents into 
the cytoplasm. However, spontaneous fusion is a low-level process at best; cells do not 
fuse with each other in nature, and it is overiy-optimistic to expect man-made cells to do 
so. At present, the promotion of fusion or endocytosis, for example, with viral coated 
proteins, is one way in which sensitive liposomes may lead to future applications that 
could well promote the usefulness of liposomes in general.
Recently, Woodle, M.C. et al (1992) reported that a novel liposome formulation, the 
stealth (a registered trademark of liposomal Tech.;Inc), with reduced RES uptake and 
prolonged circulation times had been developed. The new long-circulating liposomes have 
been used to deliver cytotoxic drugs more selectively to tumours and improve targeting of 
ligand-bearing liposomes to cells in the vascular system. Their results demonstrated the 
value of using certain long-circulating liposome formulations to deliver a peptide hormone 
(vasopressin). Many factors which influence liposomal drug delivery were addressed, 
including liposome circulation time, hormone release during circulation, blood levels of the 
'’free” peptide required for bioactivity, clearance rate of the free drug, maximum plasma 
levels that can be tolerated, and the fate of encapsulated peptide cleared with the
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liposomes. Although, a detailed characterisation of these parameters is lacking, the 
potential of such an approach may be applicable to improving the delivery of therapeutic 
agents used in the treatment of acute disorders which currently require high doses and 
frequent injections or infusions to maintain therapeutic blood levels (Woodle, M.C. et a l ; 
1992).
1.3.2 Antibodies
Antibodies are believed to hold the most promise of using protein carriers to act as a drug 
delivery system. The availability of relatively large quantities, through hybridoma 
technologies, of pure antibodies with defined specificities towards the cell surface antigens 
has made it possible to target drugs and toxins to particular tissues as well as cell types. 
The major handicaps of such processes is the inability of significant amounts of the 
complex to reach the target, and, the shedding of antigens into the general circulation. The 
fact that antigens produced by cancer cells are constantly changing further complicates the 
use of antibodies by lowering specificity of antibody-drug conjugates prepared for an 
earlier form of cancer cell (Suzuta, T.;1983, O'Neill, G.J.; 1979).
Overall, immunotoxins (that is, a monoclonal antibody acting as a carrier for a toxin which 
is linked via a chemical bond) allow the flexibility of using a wide range of carrier 
molecules, hence increasing the number of diseases for application. Of recent 
developments, immunotoxins consisting of CD4, anti-P-glycoprotein, and interleukins 
have been used selectively to kill HIV-infected cells (Till, M.A. et al; 1988), multiple drug 
resistant (MDR) cells (Fizgerald, D.J. et al; 1987), and various cells expressing growth 
factor receptors (Ogata, M. et al; 1988, Chaudhary, Y.K. et al; 1987), respectively. 
Chimeric toxins have also been produced by genetic engineering technology using fused
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toxin-carrier genes. This technology to carry out conjugation reactions and reduces the 
number of purification steps necessary to obtain the pure immunotoxin (Shen, W-C. et al; 
1992).
1.3.3 Lectins
Lectins are glycoproteins which have the affinity towards specific carbohydrate and sugar 
residues on the cell surface. Several lectins have been used as carriers to increase the 
binding and uptake of proteins in mammalian cells. For instance, wheat germ agglutinin 
(WGA), a plant lectin, binds sialic acid and N-acetylglucosamine residues on the cell 
surface and enters the cells by adsorptive endocytosis. Conjugates of WGA with HRP are 
endocytosed and subsequently transcytosed across the brain capillary endothelium. The 
Golgi apparatus has been implicated in the transcytosis of the WGA-HRP conjugates 
across the blood brain barrier (Sharon, N. & Lis, N.;1989, Broadwell, R.D. et al; 1988).
1.3.4 Polylysines
Polylysine, is just one of a number of synthetic polymers which has been used as a carrier 
of bioactive agents in all facets of drug delivery. The approach to delivering polymeric 
drugs site specifically has generally followed one of two routes:-
1. The polymeric drug acts as a lysosomotropic agent, and this relies on the concept of 
lysomotropism to attain specificity; or
2. Homing devices - antibodies, hormones, or receptor-specific sugar residues - are used 
to concentrate the polymeric drug at its target.
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Without a mechanism for concentrating the drug-carrier complex at the target site, there is 
probably little hope that variations in the endocytic activity of cell type will be adequate to 
achieve significant site selectivity.
Poly(L-lysine) is a water-soluble, cationic homopolymer of repeating L-lysine units. It has 
many characteristics that would indicate its usefulness as a drug carrier including:-
1. It has some affinity for negatively charged cancer cells.
2. It appears to be taken up by endocytosis.
3. It is very susceptible to degradation by trypsin and therefore is biodegradable.
Major drawbacks of poly(L-lysine) are biological activity and its toxicity to animals at 
elevated doses or in high molecular-weight forms.
In vitro experiments whereby poly(L-lysine) has been incorporated as a drug carrier for 
methotrexate, daunomycin, adriamycin and 6 -aminonicotinamide have been attempted. 
Despite successful inhibition of various tumour cell lines in vitro, drug-poly(L-lysine) 
conjugates have shown little effectiveness when tested in vivo. It is apparent that 
extrapolation of results obtained in vitro to events expected in vivo can be misleading. 
Mechanisms for the distribution and metabolism of polymeric drugs are generally missing 
in most in vitro tests. It is therefore not surprising that a poor correlation often exists 
between in vitro and in vivo results.
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1.3.5 Dextrans
Dextran, a polysaccharide, has been used as a plasma expander but also has been studied 
as a drug carrier. The advantages of dextran as a drug carrier are:-
1. High water solubility.
2. Well characterised chemical structure.
3. Availability of different molecular weight fractions.
4. Low toxicity.
5. Low pharmacological activity.
6 . Protection of conjugated drugs from biodegradation.
Drugs can be coupled to the hydroxyl groups of dextran an a variety of ways including 
periodate oxidation, cyanogen bromide activation and diazotization.
One of the best documented examples of dextran used as a drug carrier, is its conjugation 
to mitomycin C. Mitomycin C, injected as the free form, was rapidly cleared from plasma 
of rats. On the other hand, when conjugated with dextran, mitomycin C was retained for a 
considerably long period. It must be noted that, even when conjugated to dextran, 
sustained plasma concentrations of free mitomycin C were obtained. Thus, mitomycin - 
dextran conjugates are considered to act as a reservoir of mitomycin C which behaves 




Hormones, are an additional example of protein carrier used in drug delivery. Since they 
exert their effect after binding to specific receptors, on their target cells, attempts have 
been made to deliver drugs to specific cells via hormone carriers. Some hormones 
investigated as drug or toxin carriers include human placental lactogen (Chang, T.M., et 
al; 1977), human chorionic gonadotropin (Oeltmann, T.N. & Heath, E.C.; 1979), 
epidermal growth factor (Crowley, D.B.;1980) and melanotropin (Pozansky, M.J. & 
Olela, L.C.; 1980). Only the latter, melanotropin-drug conjugates, were actually tested in 
vivo, and although in vitro results looked promising, the in vivo studies resulted in poor 
efficacy (Varga, J.M. & Asato, N.; 1983).
Daunomycin was linked to melanotropin via the e-amino groups of lysine and its terminal 
group, aspartate. DBA mice were injected with 2 x 106  melanoma cells. This was 
followed by subcutaneous injections of daunomycin-melanotropin conjugate, either 
concomitantly or one or two weeks later, at a site distant from where the melanoma cells 
were injected. Most of the animals injected simultaneously with melanoma cells and 
daunomycin-melanotropin were dead at two weeks.
Reasons for this lack of success include, the possibility that the cutaneous melanocytes 
were not the only noncancer cells possessing MSH receptors. In addition, endogenous 
ligands may have been competing for a finite number of receptors on target cells. 
Alternatively, rapid clearance could have produced such results (Friend, D.R. & Pangbum,
S.; 1987).
Although these attempts were unsuccessful, knowledge of a hormone's receptor 
characteristics, such as cell-type specificity, and whether or not the drug-hormone
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conjugate is internalised, may improve the use of hormones in site-specific drug delivery. 
The section following this takes a more detailed look at the possibility of peptides used in 
drug targeting.
1.4 Peptide Drug Targeting
As mentioned previously, the purpose of drug targeting is to reduce toxic side effects and 
increase the therapeutic index. As discussed in section 1.3 above, drugs have been linked 
to a wide variety of carriers, namely antibodies, glycoproteins, lectins, DNA and 
liposomes. Few such drug-carrier complexes have reached the stage of clinical trials.
Hormones may offer some advantages compared to other substances for the following 
reasons:-
1. They are relatively easy to obtain in chemically pure form, due to the ease of synthesis 
and low expense.
2. They are not bound by Fc receptors on macrophages.
3. Because hormones are structurally identical or very similar in different species, no 
immunogenic reactions are expected.
The mechanism of action of the polypeptide/hormone is that the hormone binds to the 
receptor - an essential requirement for hormone action. The chemically well characterised 
hormone interacts with the poorly characterised receptor, an integral protein of the plasma 
membrane, in a saturable fashion to form a hormone-receptor complex. The magnitude of 
the hormone-receptor complex at the cell surface is a major determinant of the magnitude 
of the response. The concentration of hormone at any given time at the cell surface is a
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function of the concentration of the hormone bound and hormone internalised. Similarly, 
the concentration of receptor is critically determined by the amount of membrane 
internalised; internalisation, therefore, provides a simple mechanism that couples hormone 
degradation with receptor regulation. Overall there are several diverse functions of the 
hormone receptor complex. These include the fact that both membrane and intracellular 
biological activities are linked in some way to the hormone-receptor complex; degradation 
of the ligand is linked to the binding of the ligand; and ligand-induced regulation of the 
receptor is linked to the initial binding process (Gorden, P. et al; 1980).
Overall, hormone-receptor interactions are unique in three areas. These are cross- 
recognition of structurally similar hormones, for example, M-Daunomycin could be 
recognised by cells carrying ACTH and LPH receptors, since the peptide sequence of 
melanotropin contains a homologous region with ACTH, LPH and other portions of the 
untailored stem hormone of the ACTH family (Lowry, P.J.; 1977). Structural homology of 
hormones need not be the only reason for cross-recognition of the same hormone by 
different receptors. There are indications that cell surface receptors are not strictly 
monospecific. The best studied examples are the antigen combining sites for which the 3 
dimensional structure of receptor-ligand complexes have already been analysed by X-ray 
crystallography. In addition, interaction of p-melanotropin with the combining sites of 
immunoglobulins: 4 out of 10 randomly chosen myeloma proteins were found to bind 
proteolytic fragments of p-melanotropin. Finally as it follows from the multispecificity of 
receptors, the frequency of the occurrence of ligand-receptor interactions is a function of 
binding energy. A ligand may interact with one type of receptor with a relatively high 
energy of binding (e.g. Kq 1 0 9 lmol’1) or alternatively may bind to a great number of 
receptors with lower binding energies (K0  106 lmoH). In view of this, it can be clearly
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seen that it is essential to take great care when choosing a toxin. For instance, if it only 
takes a few toxin molecules to be lethal to the cell, then occupation of a few low affinity 
receptors by the hormone-toxin conjugate may lead to the destruction of a great variety of 
cell types carrying low affinity receptors for the hormone (Varga, J.M. & Asata, N.; 
1983).
The fact that hormones generally exert their effect after binding to specific receptors on 
their target cells enhances the potential of using them in selective drug targeting. The 
distribution of the molecules will therefore be restricted to those compartments in the 
body, which can be accessed by the available transport mechanism for each type of 
molecule (McMartin, C.; 1988). Examples where toxins have been coupled to naturally 
occurring peptides and their therapeutic usefulness studied are summarised below:-
1. Ricin. This has been linked to the cell-specific subunit of human chorionic 
gonadotropin (hCG). However, its effect was found to be less efficient than for free ricin 
itself.
2. Diphtheria toxin. This was conjugated via disulphide linkages to human placental 
lactogen. Although the conjugate was bound effectively, the receptor was unable to 
mediate the entry of the toxin A fragment.
Both examples emphasise the point that it is not enough for the hormone to bind 
effectively to its cell surface receptor if internalisation does not occur. Bearing this in 
mind, selection of a hormone as a vector in site-specific drug delivery requires knowledge 
of its receptor characteristics, such as cell type specificity, and whether or not the drug- 
hormone conjugate is internalised. One such hormone which has been studied extensively 
is MSH (a-melanocyte stimulating hormone), and a brief description of it will now be 
carried out since it, and its analogues form the basis of this study.
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1.4.1 Melanocyte Stimulating Hormone
a-MSH is a pituitary tridecapeptide,
Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
Figure 1.2: Structure of a-MSH
and is one of several chemically and biologically related peptides which may be derived 
from a large molecular weight precursor protein, pro-opiomelanocortin, in the vertebrate 
pituitary and hypothalamus (Sawyer, T.K.; 1982). The site of interaction of the hormone 
with the cell is a specific receptor localised on the plasma membrane. Secretion of the 
hormone by the pituitary is under control of the hypothalamus and is subject to circadian 
rhythm. Various peripheral tissues are MSH sensitive, primarily the skin, where 
melanocytes are sited. Circulating hormone is mainly inactivated by the skin and skeletal 
muscles as well as the kidneys, liver, lung and intestines. The inactivation is due to 
enzymatic cleavage primarily by an endopeptidase at Phe7 -Arg8  in the sequence, followed 
by exopeptidase causing degradation to free amino acids. The peptide is also synthesised 
and secreted within the brain, it is considered a neuropeptide with various CNS related 
effects on development, adaptive behaviour, learning, neurotransmission and nerve 
regeneration (Eberle, A; 1988; Leiba, H. et al; 1990).
Distribution of the native peptide is not well understood. However when a radiolabelled 
MSH analogue was injected into B16 melanoma bearing mice, initial uptake occurred in 
the kidney, spleen, tumour and adrenals. No preference was displayed for the tumour and 
transport across the blood-brain barrier was minimal Bolognia, J. et al; (1989).
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The primary effect of MSH in the pituitary is related to skin darkening, it stimulates 
melanogenesis, proliferation and differentiation of melanocytes. The complex process of 
skin pigmentation although well defined in other species, for example, amphibia, is less 
well defined in man. Skin darkening is basically caused by cell melanisation by melanin 
involving the enzymatic oxidation of tyrosine to melanin (Aroca, P. et al; 1989; Jara, J. et 
al; 1989).
The site of interaction of the hormone with the cell is a specific receptor localised on the 
plasma membrane. MSH binding and subsequent signal transduction appears to require 
extracellular calcium. Binding stimulates adenylate cyclase causing intracellular levels of 
cAMP to rise, this in turn activates protein kinases and causes protein phosphorylation 
(Eberie, A; 1988). It is unknown how the signal caused by MSH binding is terminated, but 
one or more of three possibilities is thought to occur: -
1. Dissociation of MSH from the receptor.
2. Internalisation of the receptor-ligand complex.
3. Inactivation of MSH.
Although at least part of the receptor/ligand complex is known to be internalised, its 
intracellular pathway and localisation is not defined as yet (Panasci, P. et al; 1987).
Recent studies have provided significant improvements over earlier systems for 
radioligand binding, although most analogues of a-MSH used still possess technical 
limitations, such as, relatively low specific activity with subsequent uncertainty in 
determinations of biological activity, lack of demonstration of biological activity in' 
mammalian cells, and susceptibility to metabolic degradation. Sawyer and his colleagues
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have developed a superpotent and enzymatically resistant a-MSH analogue, namely, 
[Nle4 ,D-Phe7] a-MSH (Sawyer, T.K. et al; 1980). They demonstrated unique biological 
properties including, prolonged biological activity, enhanced potency relative to a-MSH in 
a number of biological systems, and resistance to degradation by serum enzymes (Tatro, 
J.B., et al; 1990).
Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
Figure 1.3: Structure of [Nle4, D-Phe7 ]a-MSH
The use of a-MSH and its analogue, [Nle4, D-Phe7 ]a-MSH as drug carriers have several 
advantages in addition to their targeting properties. These include the ease of obtaining 
them in a pure form, the small size which avoids the problems associated with larger 
conjugates, the ability to study chemical manipulations in the peptide sequence and 
possible low immunogenicity due to their structural similarity. However, to understand the 
full potential in selective drug delivery, the binding of the analogues to the a-MSH 
receptor, followed by internalisation and subsequent fate of the ligands must be examined 
in detail. This is the major aim of the study presented here. The analogue primarily used is 
[Nle4, D-Phe7] a-MSH and the cellular system involved, is the B16 murine melanoma cell.
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1.4.2 The fate of [Nle4,D-Phe7]a-MSH after binding to the a-MSH receptor
As was discussed in the preceding two sections, it has been proven that binding of a 
peptide to its receptor is not enough when targeting of drugs is concerned using a 
lysosomotropic system. The ligand must be internalised to the cell in order to be effective. 
It will therefore be a very necessary part of this study to monitor the trafficking of 
[Nle4 ,D-Phe7] a-MSH in B16 melanoma cells. No work has been reported on such a 
system, and hence, the research carried out regarding this area could prove invaluable 
whenever a-MSH analogues are considered as drug targeters. It is essential to have 
information regarding peptide ligand uptake for such a process. If it is found that 
internalisation results in movement of the ligand to the lysosomal compartment, this will 
be of great use as far as drug choice is concerned for lysosomotropic system.
The method by which individual cellular components can be characterised, involves the 
process known as cell fractionation. Such a process, can be used to dissect the endocytic 
pathway in the respect that radioligands can be monitored in the various fractions of the 
cell representing the different cellular components. For instance, if upon cell binding, 
[Nle4 JD-Phe7] a-MSH is internalised and makes its way along the endocytic pathway to 
the lysosome, then the fractions containing the lysosomes should also contain the 
radiolabelled ligand. Each component of the cell can be identified using enzyme assays 
specific for that component For example, the plasma membrane may be characterised by a 
number of enzymes including, Na+K+ATPase, adenylate cyclase and alkaline 
phosphodiesterase I, to name but a few. On the other hand, lysosomes are identified by 
acid phosphatase, p-glucuronidase and p-hexosaminidase.
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1.5 Overview
In order to assess the binding, internalisation and fate of [Nle4 ,D-Phe7] a-MSH, it is first 
necessary to confirm that internalisation does occur, and, is dependent upon the a-MSH 
receptor. Investigations to be carried out include cellular binding experiments both at 4°C 
and metabolic temperature, 37°C, to determine internalisation of the ligand. If such a 
process is found to occur, further studies regarding the fate of the ligand after it enters the 
cell will be performed.
Finally, a study regarding size of the ligand and its effect on the rate of internalisation will 
be carried out. The same basic analogue, [Nle4 ,D-Phe7] a-MSH will be employed, 





2.1.1 Cell Culture Reagents and Buffers 
RPM I1640 + FCS
The media used for the growth of the B16 melanoma cells was RPMI 1640. Table 2.1 lists 
the individual components used in its preparation, and the various quantities required of 
each reagent. The media was prepared in an aseptic manner.
REAGENT VOLUME(MLS) SUPPLIER
DOUBLE DISTILLED DEIONISED WATER 450 N/A
RPMI 1640 50 Imperial Lab (UK) Ltd .
FOETAL CALF SERUM 50 G ibco
7.5% NaHC03 13.5 FlSONS
MEM NONESSENTIAL AMINO ACIDS 5 Imperial Lab (UK) L td .
PENICILLIN /  STREPTOMYCIN 5 Imperial Lab (UK) Ltd .
L-Glutamine 5 Imperial Lab (UK) L td .
Table 2.1: Formula of RPMI 1640 + FCS medium.
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Preparation of NaHC( > 3  (7.5%)
75g of NaHCC>3 was weighed and dissolved in lOOOmls of double distilled deionised 
water. Volumes of lOOmls were transferred to 100ml tissue culture glass bottles and 
sterilised by autoclaving for 15 minutes at 121 °C in a Drayton Castle Laboratory 
Steriliser. The buffer was stored at room temperature and was prepared fresh on a 
monthly basis.
Other Reagents
All other reagents were used directly as obtained from the supplier, however, the 
following storage protocols were followed.
Foetal Calf Serum: This was received in 500ml bottles from Gibco and was aliquoted 
into 100ml samples and stored at or below -20°C.
Penicillin / Streptomycin: This was received in 100ml bottles from Imperial Lab (UK) 
Ltd. and was aliquoted into 5ml samples and stored at or below -20°C.
L-GIutamine: as for penicillin / streptomycin.
SERUM FREE RPMI 1640
This was prepared in the same way as RPMI 1640 + FCS, however, no foetal calf serum 
was added and the volume replaced by an extra 50 mis of double distilled deionised water. 




One PBS tablet supplied by Dulbecco A was dissolved in lOOmls of double distilled 
deionised water and sterilised. This was prepared on a monthly basis and stored at room 
temperature.
0.02% EDTA
O.lg of EDTA was dissolved in 500mls of double distilled deionised water containing 5 
PBS tablets. After sterilisation by autoclaving, 20 ml samples were transferred to glass 
universal bottles and stored at or below -20°C for no longer than one month.
20mM NH4C1
A 10 times concentrated solution of NH4 CI (200mM) was prepared by dissolving 10.70g 
NH4 CI in 1 litre of double distilled deionised water. A 1 in 10 dilution was achieved by 
adding 50mls to 450mls serum free medium to give a working concentration of 20mM 
NH4 CI.
LEUPEPTIN
A 100 times concentrated solution of leupeptin (lmgml'1) was prepared by dissolving lmg 
of leupeptin in double distilled deionised water. A 1 in 100 dilution was achieved by 




A 100 times concentrated solution of pepstatin A (lmgmT1) was prepared by dissolving 
lmg of pepstatin A in 1ml of methanol. A 1 in 100 dilution was acheived by adding 1ml to 
lOOmls of serum free medium to give a working concentration of lOjigml-1.
PMSF
A stock solution of 200mM PMSF was prepared in ethanol, aliquoted into screw top 
eppendorffs (lOOp.1) and stored at or below -20°C for up to 9 months. A working 
concentration of ImM was acheived by a 1 in 200 dilution in homogenisation buffer.
ImM EDTA
0.037g of EDTA was dissolved in lOOmls double distilled deionised water. Aliquots of 
20mls were transferred to glass universals and stored at or below -20°C.
2.1.2 Binding Buffer
The table below indicates the reagents included in the binding buffer:
REAGENTS STOCK CONC. WORKING
CONC.
SUPPLIER
HEPES 250mM 25mM FlSONS
BSA 2% 0.2% Sigma
1,10-PHENANTHROLINE 0.13M 0.013M Sigma
Table 2.2: Formula for the binding buffer.
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Preparation of Stock Solutions
HEPES
6 g of HEPES was dissolved in lOOmls of serum free medium and buffered to pH 7.4 with 
1M NaOH. Aliquots of 5mls were stored in 5ml bijou bottles at or below -20°C and 
prepared on a monthly basis.
BSA
2g of BSA were dissolved in lOOmls of serum free medium. Aliquots of 5mls were stored 
in 5ml bijou bottles at or below -20°C and prepared on a monthly basis.
1,10-Phenanthroline
0.3g of 1,10-phenanthroline was dissolved in 10 mis of 95% ethanol and stored at or 
below -20°C.
Preparation of Binding Buffer
5mls of HEPES stock solution, 5mls of BSA stock solution and 5p.l of stock 1,10- 
phenanthroline was made up to 50mls with serum free medium in a grade A volumetric 
flask. This was prepared directly before use.
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2.1.3 Homogenisation Buffer
Four buffers were tested and the formulae for all four outlined Table 2.3:
BUFFER REAGENTS CONCENTRATION SUPPLIER
1 NaHCOa ImM Sigma
DTT ImM Sigma
2 NaHCOa ImM Sigma
DTT ImM Sigma
sucrose 0.25M FlSONS
3 Tris-HCl 0.05M F isons
4 Tris-HCl 0.05M F isons
sucrose 0.25M F isons
Table 2.3: Formulae for homogenisation buffers tested.
Preparation of buffers
Buffer 1
0.0084g of NaHCC>3 and 0.0154g of DTT were dissolved in lOOmls of double distilled 
deionised water.
Buffer 2
0.0084g of NaHCC>3 , 0.0154g of DTT and 9mls of 6 6 % sucrose were dissolved in and 
made up to lOOmls with double distilled deionised water.
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Buffer 3.
0.6g of Tris base was dissolved in 60mls of double distilled deionised water, buffered to 
pH 7.2 with 1M HC1 and then made up to lOOmls with double distilled deionised water.
Buffer 4
0.6g of Tris base was dissolved in 60mls of double distilled deionised water, buffered to 
pH 7.2 with 1M HC1, 9mls of 6 6 % sucrose added and the whole mixture made up to 
lOOmls with double distilled deionised water.
All buffers were prepared on a monthly basis and stored at 4°C.
2.1.4 Acid Wash Buffer
A 0.1M citrate buffer was chosen as the buffer for the acid treatment of the cells after 
binding experiments had been performed. It was prepared as follows:-
21.01g of citric acid (Fisons), 5.43g NaCl and 23.44mls of 1M NaOH were made up to 1 
litre with double distilled deionised water. This formula give the required pH of 2.5, 
adequate for the removal of externally bound ligand from the surface of the cells. The 
buffer was stored at 4 °C and prepared on a monthly basis.
Note a series of buffers of varying pH's (pH2 to pH 5) were prepared to determine the 
optimum pH for removal of extracellularly/surface bound ligand. Figure 2.1 on page 35 
illustrates the effect of different pH on the efficiency of removing ligand extracellularly 
bound for a series of cell well experiments where the level of total binding at 37°C was 











Figure 2.1: The effect of different pH's on the efficiency of removal of extracellularly 
bound ligand.
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2.1.5 Sucrose Gradient Buffers
A 6 6  % (w/w) sucrose stock solution was prepared by dissolving 17 lg of sucrose in 
90mls double distilled water. The required concentrations of 60% and 10% were then 
prepared as follows.
60%: 89mls of 6 6 % sucrose + 1 lmls Tris-HCl 
10%: 1 lmls of 6 6 % sucrose + 89mls Tris-HCl
These were stored at 4°C and prepared on a monthly basis.
2.1.6 Ligands
The following ligands were used, and all were synthesised, purified and aliquoted by Dr G 
W J Olivier in our own laboratory.
1) Ac-[Nle4  JD-Phe7] a-MSH.
2) Na-Biotin-[Nle4 ,D-Phe7] a-MSH.
3) Streptavidin Biotin-[Nle4  J)-Phe7] a-MSH.
Each was prepared as a lmgml"* solution, whereby lmg of ligand was dissolved in 1ml of 




0.25M Phosphate Buffer, pH 7.4
This was prepared from a mixture of 0.25M Na2HPC>4 and 0.25M NaH2 P0 4
Na^HPO^: 4.45g was dissolved in 100 mis of double distilled deionised water.
NaH2 P 0 4: 3.90g was dissolved in lOOmls of double distilled deionised water.
A pH of 7.4 was achieved by adding NaH2PC>4  dropwise to Na2HPC>4. The stock 
solutions were stored at 4°C and prepared on a monthly basis. The phosphate buffer was 
prepared on the day of the iodination.
0.25% BSA
0.0125g of BSA (Sigma) was dissolved in 1ml of phosphate buffer, pH 7.4 and 4mls 
double distilled deionised water. This was prepared on the day of iodination.
0.1% Chloramine T




0.05g of polypep was dissolved in 1ml phosphate buffer, pH 7.4 and 4mls of double 
distilled deionised water directly before use.
1% TFA
lml of high purity TFA was diluted to lOOmls with double distilled deionised water and 
stored at 4°C.
80% MeOH / 1% TFA
80mls of methanol and lml TFA were diluted to lOOmls with double distilled deionised 
water and stored at 4°C.
60% MeOH / 1% TFA
60mls of methanol and lml of TFA were diluted to lOOmls with double distilled deionised 
water and stored at 4°C.
50% MeOH /1%  TFA
50mls of methanol and lml of TFA were diluted to lOOmls using double distilled deionised 
water and stored at 4°C.
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2.1.8 HPLC Solvents
Two mobile phases were required for the purification of radiolabelled ligands and were 
prepared as follows:-
Mobile Phase A: 0.1 % TFA / H ,0
This was prepared by adding 0.5mls of TFA to 499.5mls double distilled water (HPLC 
grade). The solvent was degassed thoroughly and prepared as required.
Mobile Phase B: 70% acetonitrile /1% TFA / H20
350mls acetonitrile, 0.5mls TFA and 149.5mls double distilled water (HPLC grade) were 
mixed together. The solvent was degassed thoroughly prior to use and was prepared as 
required.
2.1.9 Enzyme Assays 
p-Hexosaminidase
Reagents
4mM p-nitrophenyl a  -A-acetylglucosamine, in sodium citrate-phosphate buffer (0.1M 
with respect to phosphate), pH 4.5, stored frozen.
0.15M NaCl, stored at room temperature.
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50mM NaOH, stored at room temperature.
Alkaline Phosphodiesterase I 
Reagents
5 mM Na-p-nitrophenol 5' -thymidylate, stored frozen.
0.1M Tris-HCl, pH 9.0, stored at 4°C.
0.5M glycine, 0.5M Na2 C0 3 , stored at 4°C.
2.2 METHODS
2.2.1 Procedure for Radioiodination of Ligands
Column Preparation
A Bond Elut, C l8  reverse-phase column, spherisorb ODS (Analytical International) was 
used to carry out the separation of iodinated ligands. The column had to be prepared
before use by a series of washes as oudined below.
Wash 1: 3 x lml wash with 1% TFA
Wash 2: 3 x lml wash with 80% MeOH / 1% TFA
Wash 3: 1 x lml wash with 1 % polypep
Wash 4: 3 x lml wash with 80% MeOH / 1% TFA
Wash 5: 3 x lml wash with 1% TFA
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Care was taken with the final lml 1% TFA wash to ensure a small volume was left on top 
of the column to avoid the column from "drying out".
Iodination of Ac-[Nle4,D-Phe7]a-MSH
In a 1.5ml eppendorff, 1.5 |il of lmgml'l [Nle4 ,D-Phe7 ]a-MSH was added to 20|il of 
0.25M phosphate buffer, pH 7.4. lmCi of 125INa was then added. The reaction was 
initiated by addition of lOjil 0.1% chloramine T and allowed to proceed for exacdy 30 
seconds. By adding 0.60mls of 0.25% BSA, the reaction was terminated (Olivier, G.J.W.; 
unpublished results).
The reaction mixture was then transferred to the Bond Elut column, already prepared by 
the method described above. To separate the free iodide, mono-iodinated [Nle4 ,D-Phe7 ]a- 
MSH and di-iodinated [Nle4 ,D-Phe7] a-MSH, to some extent, the following washes were 
performed.
Wash 1: 2 x lml wash with 0.25M phosphate buffer, pH 7.4
Wash 2: 4 x lml wash with 50% MeOH / 1% TFA
Wash 3: 2 x lml wash with 60% MeOH / 1% TFA
The first 2mls of wash, i.e. phosphate buffer washing, were discarded. The remaining 6 mls
were further purified to obtain a pure fraction of mono-iodinated [Nle4 ,D-Phe7 ]a-MSH, 
the procedure for which is outlined below.
The whole reaction was carried out with great care behind lead blocks in a fume cupboard.
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Purification of [125I-Tyr2,Nle4,D-Phe7]a-MSH
A pure sample of mono-iodinated ligand was prepared using reverse-phase high 
performance liquid chromatography. The details of the equipment used was as follows:
. Milton Roy CM4000 multiple solvent delivery system with a lml loop 
. LDC Analytical Spectromonitor 5000 photodiode array detector, ^=270nm; aufs range 
0.01
. Pharmacia FRAC-100 fraction collector 
. Servogor 220 chart recorder; chart speed 12cm/h; lOmV 
. HPLC column used was reverse phase C l8 , ODS, 20cm
The 125I mixture was injected in 12 x 0.5ml aliquots onto the HPLC. The following 
gradient was performed in order to separate the free iodide, mono- and di-iodinated 
peptide:
TIME (mins) SOLVENT A (%) SOLVENT B ( %) EXPONENTIAL
0 95 5 1
5 95 5 1
50 40 60 0.5
55 40 60 0.5
60 95 5 1
Table 2.4: Gradient Method for the HPLC purification of the iodinated ligands.
lml fractions were automatically collected between 25 and 40 minutes in LP4 gamma- 
counter tubes. The 125I activity associated with each lml fraction was determined by 
transferring the tubes to the LKB Wallac 1277 Gammamaster automatic gamma-counter 
and each sample assayed for 2  minutes.
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A specimen HPLC trace of [1 2 5I-Tyr2 ,Nle4 ,D-Phe7] a-MSH purification and a trace of 
125I activity associated with the fractions collected from the HPLC are shown on the 
following two pages, figures 2.2 and 2.3. respectively. From previous studies carried out 
on "cold" iodinations of the ligand, it was found that the mono-iodinated ligand was eluted 
around 33 & 34 minutes. From the trace, the second series of high 125I activity was 
probably due to di-iodinated ligand. The mono-iodinated ligand was used in all 
experiments.
It must be noted that each time an experiment was carried out, a "fresh" iodination and 
purification was performed. In addition carrier free Na125I containing 80.5 x 1012  
degradations per second per milliatom was used to iodinate the ligands. The gamma- 
counter was approximately 70% efficient and was assumed to be invariant Thus the 
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Figure 2.2: HPLC trace of the Purification of Iodinated Ac-[Nle4,D-Phe7]a-M SH as 
measured by UV absorption at 217nm. Peaks 1, 2 and 3 are thought to represent non­
labelled, mono-iodinated and di-iodinated peptide respectively.
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Figure 2.3: Radioactivity Associated with Fractions from the HPLC Purification of 
Radio-iodinated Ac-[Nle4,D-Phe7]a-MSH from 27 minutes after the Injection sample
(Flow Rate 1 ml/minute).
45
Iodination & Purification of Na -Biotin-[NIe4 ,D-Phe7 ]a-MSH
This was as for [Nle4 ,D-Phe7] a-MSH just described, however, a lmgml' 1 solution of Na 
- biotin-[Nle4 ,D-Phe7 ]a-MSH was used. The fractions collected were between 25 and 42 
minutes.
Iodination of Streptavidin-Biotin-[NIe4 ,D-Phe7 ]a-MSH
The Na-biotin-[Nle4 ,D-Phe7 ]a-MSH was iodinated and purified as normal (as described 
above), and the streptavidin added after the iodination as outlined in the next section.
2.2.2 Preparation of Streptavidin-Biotin-[l25I-Tyr2,Nle4,D-Phe7]a  
-MSH
Na-Biotin-[Nle4 ,D-Phe7 ]a-MSH was iodinated and purified in the normal way. The 
streptavidin was then added using the following procedure:-
Stock streptavidin was 1.66 x 10-5 M (lmgml-1) and the required amount was diluted in 
PBS and added to the purified fraction of Na-Biotin-[1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH 
(Note the required amount depended on the activity of iodinated ligand available). The 
mixture was placed on an automatic shaker for 30 minutes at room temperature. At the 
end of the shaking time, the mixture was added to streptavidin coated magnetic beads and 
left for 10 minutes so as to equilibrate the beads to the magnet. The resulting supernatant 
should contain the streptavidin-biotin-[1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH and this was again 
counted in the gamma-counter to determine the total counts associated. This method was 
found to yield approimately 85-90% efficiency.
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2.2.3 In Vitro Experiments
Routine Cell Culture
B16 murine melanoma cells were grown in 175cm2 Falcon tissue culture flasks in RPMI 
1640 medium supplemented with 10% heat-inactivated foetal calf serum, 2mM L- 
glutamine, 1% MEM nonessential amino acids, 50UIml_1 penicillin and 50mgmH 
streptomycin at 37°C in a humidified atmosphere of 95% air and 5% CO2 . Confluent cells 
were detached weekly with an incubation of 2.5mls of 0.02% EDTA in phosphate 
buffered saline, pH 7.4, and counted on a haemocytometer. This procedure ensured the 
cells were at the same stage of growth for each experiment.
Cell Counting and Viability
Once the cells were detached from their flasks, they were then counted for viability. The 
following procedure was used.
1) 0.4mls of cell suspension was transferred to a test-tube.
2) 0.1ml of 0.1% Trypan blue dye was added and the mixture shaken thoroughly.
3) A small amount of the mixture was transferred to the haemocytometer chamber and , 




Figure 2.3: Haemocytometer chamber used for Cell Counting
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The number of cells per ml was calculated using the following equation:
cells / ml = (total cells in all 5 ehamberslx 104
4
The cells not containing the blue dye are the viable cells containing intact membranes, and 
only those were counted.
2.2.3.1 Internalisation of [125i.Tyr2,Nle4,D-Phe7]a-MSH at 37°C
A density of 5 x 105  cells per well were incubated in 24-well culture plates for 24 hours in 
RPMI1640 medium supplemented with 10% heat-inactivated foetal calf serum, 1% MEM 
nonessential amino acids, 2mM L-glutamine, 50IUmH penicillin and 50pgmH 
streptomycin at 37°C in a humidified atmosphere of 95% air and 5% CO2 .
They were then washed twice with ice-cold serum free RPMI 1640 medium to remove all 
serum proteins. The cells were then incubated with O.lnM [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a- 
MSH in binding buffer (25mM HEPES, pH 7.2, 0.2% BSA, 0.013mM 1,10- 
phenanthroline) in the absence or presence of excess non-iodinated [Nle4 JD-Phe7] a-MSH 
(l|iM) for various times at 37°C. At the end of the required time the binding buffer was 
discarded and the cells washed with ice-cold serum free RPMI 1640 medium. The 125I 
activity associated with the cells was determined by digesting the cells with 0.5mls 0.1M 
NaOH and assayed using the LKB Wallac 1277 Gammamaster automatic gamma-counter. 
In parallel to this some cells were treated with a 5 minute acid wash at 4°C using 0.1M 
citrate buffer, pH 2.5. The cells were then removed from the wells using NaOH digestion 
and assayed for 125I activity in the automatic gamma-counter.
48
2.2.3.2 Internalisation of [125i-Tyr2,Nle4,D-Phe7]a-MSH at 4°C
This was carried out to confirm that internalisation only occurred at 37°C. The exact same 
protocol as for "Internalisation of [ 1 2 5I-Tyr2 \Nle4 ,D-Phe7 ]a-MSH at 37°C" was used, 
except all incubations took place at 4°C.
2.2.3.3 Effect of Ammonium Chloride on the Internalisation of 
[125i«Tyr2,Nle4,D-Phe7]a-MSH
The same protocol as for "Internalisation of [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH at 37°C was 
used, however, the cells were incubated for 15 minutes at 37°C in serum free RPMI 1640 
medium containing 20mM NH4 CI prior to incubation with radiolabelled ligand Thereafter 
all buffers contained 20mM NH4 CI.
2.2.3.4 Pulse Chase Internalisation of [l25I-Tyr2,NIe4,D-Phe7]a- 
MSH
A density of 5 x 10  ^cells were incubated in 24-well culture plates for 24 hours in RPMI 
1640 medium supplemented with 10% heat-inactivated foetal calf serum, 1% MEM 
nonessential amino acids, 2mM L-glutamine, 50IUml_1 penicillin and 50|igmH 
streptomycin at 37°C in a humidified atmosphere of 95% air and 5% CO2 .
They were then washed 2 times with ice-cold serum free RPMI 1640 medium to remove 
all the serum proteins. The cells were then incubated with O.lnM [1 2 5I-Tyr2 ,Nle4 ,D-Phe7] 
a-MSH in binding buffer (25mM HEPES, pH 7.2, 0.2% BSA and 0.013M 1,10- 
phenanthroline) in the presence or absence of 1 0 0 0 -fold excess non-iodinated ligand for 2  
hours at 4°C. At the end of the 2 hour period the cells were washed with ice-cold serum
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free RPMI 1640 medium and the cells subjected to a second incubation at 37°C for 
varying amounts of time. At the end of the required time, the cells were washed with ice- 
cold serum free RPMI 1640 medium and digested with 0.1M NaOH and the 12^ I activity 
associated with the cells determined using a LKB Wallac 1277 Gammamaster automatic 
gamma-counter. A parallel series of cells were given a 5 minute acid treatment with 0.1M 
citrate buffer, pH 2.5, at 4°C, washed and digested and assayed as before.
2.2.3.5 Effect of Ammonium Chloride on the Pulse Chase 
Internalisation of [125I-Tyr2,Nle4,D-Phe7]a-MSH
The same protocol as for "Pulse Chase Internalisation of [1 2 5 I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH" 
was used, however, the cells were incubated for 15 minutes at 37°C in serum free RPMI 
1640 medium containing 20mM NH4 CI prior to incubation with radio-labelled ligand. 
Thereafter all buffers contained 20mM NH4 CI.
2.23.6 Effect of Leupeptin on the Pulse Chase Internalisation of 
[125l-Tyr2,NIe4,D-Phe7]a-MSH
The same protocol as for the "Ammonium Chloride Effect on the Pulse Chase 
Internalisation of [12^I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH" was used, except the 20mM NH4 Q  
was replaced with 1 0 |igmH leupeptin.
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2.2.3.7 Effect of Pepstatin A on the Pulse Chase Internalisation of 
[125l-Tyr2,Nle4,D-Phe7]a-MSH
The same protocol as for the "Ammonium Chloride Effect on the Pulse Chase 
Internalisation of [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH" was used, except the 20mM NH4 Q  
was replaced with lOp-gml"1 pepstatin A.
2.2.3.8 Pulse Chase Internalisation of Na-Biotin-[l25I- 
Tyr2>Nle4,D-Phe7] a-MSH
The same protocol as for the "Pulse Chase Internalisation of [125I-Tyr2,Nle4J)-Phe7]a -  
MSH", section 2.2.3.4., however the O.lnM [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH was 
substituted by O.lnM Na- Biotin-[1 2 5I-Tyr2 ,Nle4 ,D-Phe7] a-MSH.
2.2.3.9 Pulse Chase Internalisation of Streptavidin-Biotin-[l25I- 
Tyr2-Nle4,D-Phe7]a-MSH
The same protocol as for the "Pulse Chase Internalisation of [12^I-Tyr2 ,Nle4 JD-Phe7 ]a- 
MSH" was used, however the O.lnM [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH was substituted by 
0.1 nM Streptavidin-Biotin-[ 1 2 5I-Tyr2 ,Nle4 ,D-Phe7] a-MSH.
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2.2.4 Sucrose Gradient Subcellular Fractionation 
Experiments
2.2.4.1 Homogenisation
A number of methods were tested to determine the optimum conditions for cell 
homogenisation of B16 murine melanoma cells. A brief list of the various parameters 
tested are listed as follows, and a more detailed procedure outlined below.
A. Choice of Homogenisation Method: 1) Tight-fitting dounce homogeniser
2) Loose-fitting dounce homogeniser
3) Needle and syringe
B. Choice of Homogenisation Buffer: 1) ImM NaHCC>3 ; ImM DTT
2) ImM NaHCC>3 ; ImM DTT; 0.25M sucrose
3) 0.05M Tris-HCl, pH 7.2
4) 0.05M Tris-HCl, pH 7.2; 0.25M sucrose
Note all homogenisation buffers contained O.lmM PMSF and ImM EDTA.
A Choice of homogenisation method
Tight-fitting Dounce Homogeniser
A confluent layer of B16 murine melanoma cells were scraped from a 75 cm2  Falcon 
tissue culture flask using a cell scraper. These were pelleted by centrifuging at 1000 RPM 
for 10 minutes in a Jouan B3.ll Centrifuge. The cells were then suspended in PBS and
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recentrifuged as before. This was repeated once more to ensure the cells were free from all 
the serum proteins present in the RPMI 1640 medium used for growth of the cells. The 
cells were then suspended in 0.75mls of the homogenisation buffer and left for 30 minutes 
at 4°C with regular shaking. The cell suspension was transferred to the tight-fitting dounce 
homogeniser and homogenised using 5, 10, or 15 strokes of the dounce homogeniser. A 
small sample was assayed to determine the number of cells still viable. The table below 
indicates the degree of cell lysis observed for 5, 10, or 15 strokes of the dounce 
homogeniser:-





Table 2.5: % Lysis of B16 Cells after Homogenisation using the Tight-Fitting Dounce
Homogeniser.
Loose-Fitting Dounce Homogenisation
The same procedure as for "Tight-Fitting Dounce Homogeniser" was repeated, however a 
loose-fitting dounce homogeniser was used, and the number of strokes carried out were 0 , 
10,20 and 30. The table below indicates the efficiency of this method:-
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Table 2.6: % Lysis for B16 Cells after Homogenisation using the Loose-Fitting Dounce
Homogeniser.
Needle and Syringe Method of Homogenisation
The B16 cells were scraped from the flasks, pelleted, washed and suspended in 
homogenisation buffer as for the "Tight-Fitting Dounce Homogeniser". The cell 
suspension was then passed through a series of needles of different aperature size. The 
viable cells were determined at various stages throughout this procedure to determine the 





VIABLE CELLS/M L % LYSIS
NONE 1.80x10® 0
5 x21G 0.77x10® 43
+ 2 x 25G 0.15x10® 92
+ 5 x 25G 0.01x10® 100






VIABLE CELLS/M L % LYSIS
NONE 2.70x10* 0
5 x21G 1.66x10* 39
+ 5 x 23G 1.24x10* 55
+10 x 23G 0.16x10* 94
Table 2.8: % Lysis of B16 Cells after homogenisation by Needle and Syringe by the
Method specified.
For all three methods described, the homogenisation buffer used was ImM NaHC0 3 , 
ImM DTT.
At this stage it was decided that the needle and syringe method for homogenising the cells 
would be used instead of a tight-fitting dounce homogeniser. Although both methods 
resulted in 82% lysis (tight-fitting dounce homogeniser using 10 strokes) and 94% lysis 
(needle and syringe method 2 , table 2 .8 ), both acceptable values, there were certain 
advantages to the needle and syringe method. Not only was it a fast and efficient method, 
it was also a much easier apparatus to dispose off. This was a major factor to consider due 
to the fact that there would be 125I activity in the cells being homogenised after 
internalisation studies.
B Choice of Homogenisation Buffer
As stated at the beginning of this section four buffers were tested in an attempt to improve 
the efficiency of the process. The table below indicates the influence of each buffer after 
homogenising the cells by the needle and syringe method:-
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CELL TREATMENT BUFFER % LYSIS




Table 2.9: % lysis of B16 cells by various homogenisation buffers.
From these results it was decided to use the 0.05M Tris-HCl, pH 7.2; 0.25M sucrose 
(buffer D). Although little or no difference was apparent between buffer 1 and buffer 4, it 
was assumed that the hypotonic nature of the NaHCC>3/DTT buffer would result in more 
damage to the lysosomes. The addition of 0.25M sucrose to the Tris-HCl buffer not only 
helped its efficiency but also meant the sample was already suspended in a sucrose 
solution and so could be directly layered onto the gradient.
In conclusion to this section is a summary of the homogenisation method finally chosen:- 
Needle and syringe : 5 x 21G + 5 x 23G
Homogenisation buffer: 0.05M Tris-HCl, pH 7.2 / 0.25M sucrose
2.2.4.2 Centrifugation
Preparation of Linear Sucrose Gradient
A MSE Model 570 Gradient former was used to prepare the linear sucrose gradients 
ranging from density 1.000 to 1.300 gem’1. A photograph of the apparatus is shown on 
page 58.
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To set the gradient former to the required state in order to obtain a 5ml linear gradient, the 
following protocol was followed:
Both syringes and all tubes were filled with double distilled water. The speed control was 
then set to maximum, i.e. 10. The right hand syringe delivery volume was set at 2.5mls 
and the gradient former switched on. Once the cycle was completed, the system was 
immediately switched off. The left hand syringe delivery volume was then set to 2.5mls 
also, and the machine switched on and the reverse button pressed. At the end of the cycle 
the machine was immediately switched off. The double distilled water was then flushed out 
of the system and replaced with the appropriate sucrose solutions. These were 60% in the 
right hand syringe and 10% in the left hand syringe. It was always necessary to ensure no 
air bubbles were in the system. To obtain a 5ml gradient ranging from 1.000 to 1.300 
gem-3, the speed was adjusted to 3.5 and the machine switched on. Each gradient took 40 
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Figure 2.4: MSE Model 570 Gradient Former (Front View).
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Centrifugation of Cell Homogenate
Approximately 0.5mls of the cell homogenate prepared in 0.05M Tris-HCl, pH 7.2 
containing 0.25M sucrose was layered carefully on top of the linear gradient. This was 
best done using a pasteur pipette and gently running the cell homogenate down the side of 
the tube onto the top of the gradient. Each sample was loaded and carefully monitored to 
ensure the tubes would be balanced for the centrifugation stage.
Once layered onto the gradient, the linear gradients containing the homogenised sample 
were transferred to the SW40.1 rotor and centrifuged in a Beckmann Ultracentrifuge at 
35,000 RPM for 90 minutes at 4°C.
2.2.4.3 Fractionation of the Linear Gradients
On completion of the 90 minute centrifugation, the tubes were carefully removed from the 
arms of the SW40.1 rotor. Special care was taken to avoid mixing of the gradients. 
Fractions of 200|il were then removed from the top of the gradient and transferred to LP4 
gamma-counter tubes.
2.2.4.4 125I Activity of the Fractionated Cell Homogenate
The 200|il fractions obtained as described above were assayed for the counts per minute 
activity using a LKB 1277 Wallac Gammamaster automatic gamma-counter. The 
tubes were placed in the gamma-counter and the counts per minute determined for 1 2 0  
seconds.
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2.2A.5 Density of the Centrifuged Fractions
The density of each fraction was determined by the indirect method of refractive index. A 
table of the refractive indexes of a number of different concentrations of sucrose are 
presented in Appendix A .
A drop of each fraction was placed on a prism and a light "step" aligned manually with 
cross-hair. The apparatus used for measurement of the refractive indices was maintained at 
25°C to eliminate the effect change of temperature on the values obtained. The refractive 
indices were then converted into density from the table in Appendix A .
2.2.4.6 Enzyme markers 
p-Hexosaminidase
50jil of the fraction was transferred to a 5ml test-tube and 100|il of the buffered substrate 
added. The volume was adjusted to 200|il with saline. After 4 hours at 37°C, the reaction 
was stopped by addition of 0.5ml of 50mM NaOH. The slightly turbid solution was 
clarified by centrifugation, and the absorbance measured at 400nm against a reagent blank 
using a Milton Roy Spectronic 601 Spectrophotometer.
Alkaline Phosphodiesterase I
The reaction mixture was prepared by mixing 0.1ml substrate solution, 0.1ml Tris-HCl 
buffer and 0.2ml water. 50}il of fraction was then added and the whole mixture incubated 
at 37°C for 2 hours. The reactions were then stopped by addition of 1.0ml glycine /
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Na2 C0 3  , and their absorbance read at 410nm against a reagent blank using a Milton Roy 
Spectronic 601 Spectrophotometer..
2.2A.7 Cell Binding of [125l-Tyr2,Nle4,D-Phe7](X-MSH f°r 
Subcellular Fractionation Experiments
Internalisation of [125I-Tyr2,Nle4,D-Phe7]a-MSH
B16 cells were grown to confluency on a 75cm2  Falcon tissue culture flask. The cells were 
washed with ice-cold serum free RPMI 1640 medium prior to incubation with O.lnM 1 2 5I- 
[Nle4 J)-Phe7 la-MSH at 37°C or 4°C for varying amounts of time, in binding buffer in the 
presence or absence of 1000-fold excess non-iodinated ligand. At the end of the required 
time, the binding buffer was removed and the cells thoroughly washed with ice-cold serum 
free medium. The cells were then scraped from the flasks and homogenised, centrifuged, 
fractionated and assayed for enzyme markers, density and 125I activity. In a parallel flask a 
5 minute acid treatment was carried out to distinguish between internalised ligand and 
externally bound ligand.
Pulse Chase Internalisation of [125I-Tyr2,Nle4,D-Phe7]a-MSH
The same method was used as for cell well experiments (section 2.2.3.3), however cells 
were grown to confluency in a 75cm2  flask and the binding carrried out on a confluent 
monolayer of cells. Homogenisation, centrifugation, fractionation, enzyme marker assays, 
density measurements and 125I activity were assayed as described in the above sections.
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CHAPTER 3
INTERNALISATION OF [125I-Tyr2- 
Nle4,D-Phe7](X-MSH.
3.1 INTRODUCTION
[Nle4 JD-Phe7] a-MSH is a potent melanotropin which stimulates tyrosinase, resulting 
in melanogenesis, after interacting specifically with a MSH (melanocyte-stimulating 
hormone) receptor at the plasma membrane of B16 murine melanoma cells. Previous 
workers in the field (Eberle, A.N.;1977) confirmed that [Nle4 ,D-Phe7] a-MSH binds 
specifically to the MSH receptor and is 10-fold more potent than a-MSH itself. 
Although it has been reported that internalisation of the ligand after its initial binding 
occurs (Panasci, L.C. et al\ 1987), no information exists on what happens after 
internalisation. The experiments described in this section, were designed to study the 
phenomenon of internalisation of [1 2 5I-Tyr2 ,Nle4 ,D-Phe7] a-MSH (the mono-iodinated 
form), and once internalised, the fate of the ligand.
Internalisation was determined quantitatively by introduction of an acid dissociation 
technique. The theory behind this method is that the acid wash removes all ligand 
bound to the surface of the cell, including that bound to the plasma membrane. It 
would then be correct to say that any iodinated activity associated with the cells 
following the acid wash, was that present inside the cells, either in a degraded or non­
degraded form. After internalisation was found to occur, it was then of interest to 
determine what happened to the ligand. The use of an exogenous amine, ammonium 
chloride was chosen to aid this field of study. Ammonium chloride, is known to trigger 
a pH rise in various acidic compartments of the cell, such as endosomes and
lysosomes. The immediate consequence within the lysosomes is thought to be an
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inactivation of proteolytic enzymes which have acidic optimum activity in media. 
Another consequence is thought to be general perturbation of vesicular traffic within 
the cells and of intracellular compartmentalisation resulting in modifications of the 
pathways of internalised materials, such as, hormone-receptor complexes. Therefore, if 
upon internalisation the [1 2 5I-Tyr2 ,Nle4 ,D-Phe7] a-MSH made its way to the lysosome 
and was subsequently degraded, the presence of NH4 CI would inhibit such a pathway. 
Thus the presence of NH4 CI (20mM) was introduced into the experiment in order to 
study the fate of internalised ligand. It must also be noted at this point, that the chapter 
following this deals with the fate of the internalised ligand by use of subcellular 
fractionation techniques.
One final aspect to be studied concerning the internalisation of [1 2 5I-Tyr2 ,Nle4 »D- 
Phe7] a-MSH dealt with was the incorporation of some protease inhibitors, namely 
leupeptin and pepstatin A. These would inhibit to some extent the enzymes responsible 
for the degradation of the ligand-receptor complex.
3.2 METHODS
These were described in detail in chapter 2.
3.3 RESULTS
3.3.1 Cell Binding of [l^Si.Tyr^NIe^D-Phe^la-MSH to B16 Melanoma 
Cells at 4°C
[1 2 5 I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH (O.lnM), was bound to 5  x 1 0 5  B16 melanoma cells 
in a 24-well tissue culture plate for various periods of time at 4°C, and in the 
presence or absence of 10'6M non-iodinated ligand. At the end of the required time,
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the binding buffer containing unbound ligand was discarded and the layer of cells 
washed with ice-cold serum free RPMI 1640 medium. They were then removed by 1M 
NaOH digestion and the 125I associated with the cells determined. A parallel series of 
wells was given the acid wash treatment, incubated for 5 minutes with 0.1M citrate 
buffer, pH 2.5 prior to digestion with NaOH.
Figure 3.1 on page 69 represents the data obtained for binding of [1 2 5I-Tyr2 ,Nle4 ,D- 
Phe7 ]a-MSH at 4°C. All data points represent the mean and standard deviation from 
four wells and show a very small degree of variation. Non-specific binding was 
assessed in the presence of 10'6M non-iodinated [Nle4 ,D-Phe7] a-MSH. Specific 
binding was obtained by subtracting the non-specific binding from the total binding.
At 4°C specific binding was still increasing at 4 hours, as was non-specific binding. The 
amount of ligand associated with the inside of the cells remained low compared with 
specific binding and this would suggest that at 4°C, little or no internalisation occurred.
3.3.2 Cell Binding O f [125l-Tyr2, Nle4,D-Phe7]a-MSH to B16 Melanoma 
Cells at 37°C
The experiment to study the cell binding of the ligand at 4°C (as described in section 
3.3.1) was repeated at 37°C. The results are shown in Figure 3.2 on page 70.
The data obtained at 37°C was noticeably different to the 4°C results. At 37°C, the 
apparent specific binding of [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH reached a maximum at 60 
minutes and then decreased for the remaining time of the experiment The acid-wash 
data (internalised ligand) showed a similar result to the specific binding. An increase in 
activity was evident between 0  and 60 minutes, and a gradual decrease occurred after 
this time. It must be noted that the amount of ligand within the cell decreased to a
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lesser degree than that specifically bound. In fact at 240 minutes more than 70% of the 
1 2 5 1 activity associated with the cells at the 60 minute time period was present in the 
case of the acid treated cells. This compares to only 50 % for the same time period 
differences for the ligand specifically bound to the cells. At 37°C, [12 5I-Tyr2 ,Nle4 ,D- 
Phe7] a-MSH was internalised by the B16 cells, however, it has not been determined 
whether this is in a complete or fragmented form. After 60 minutes, 40% of the cell- 
associated activity was within the cells.
3.3.3 The Ammonium Chloride Effect on the Internalisation of [125j_ 
Tyr2,Nle^,D-Phe^]a-MSH with B16 Melanoma Cells
The experiment described in section 3.3.2 confirmed that internalisation of the ligand 
occurred at 37°C. It was then necessary to determine the fate of the ligand, and the 
reason for the decrease in the ligand associated with the cells after 60 minutes.
One reason for such a phenomenon occurring, may be that the ligand was degraded 
within the cells. Hence, the incorporation of NH4 CI, a lysosomotropic agent into the 
system. NH4 CI raises the pH of the lysosomes hence inactivating proteolytic enzymes 
with acidic pH optima.
A "binding" experiment was performed at 37°C, and 20mM NH4 CI was introduced 
into the system. A pre-incubation of the cells at 37°C in serum free RPMI 1640 
medium containing 20mM NH4 CI was carried out, and all buffers thereafter contained 
20mM NH4 Q.
The graph in Figure 3.3 on page 71 is a typical experiment of the binding of [1 2 5I- 
Tyr2 ,Nle4 ,D-Phe7] a-MSH at 37°C in the presence of 20mM NH4 CI. Non-specific 
binding remained low throughout the 240 minutes duration of the experiment. This
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correlates with what was observed in the same experiment but in the absence of the 
NH4 CI. However, the specific binding and acid-wash data differed greatly in the 
presence and absence of the NH4 CI. Specific binding continued to increase over the 
whole 240 minute period, as did the acid-washed values. Moreover, at 240 minutes, 
90% of the cell-associated ligand was internalised, compared with only 40% in the 
experiment not containing any NH4 CI (Figure 3.2).
3.3.4 Time Dependence of the Internalisation of the [125i_Tyr2,Nle4,D- 
Phe^]a-MSH into B16 Melanoma Cells
Here a set of experiments were set up to study more closely the time course of the 
internalisation of the [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH. They involved an incubation of 
the cells for 2 hours at 4°C in the presence of O.lnM [12 ^I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH. 
After this time, the unbound ligand was removed and the cells subjected to a second 
incubation in serum free RPMI 1640 medium at 37°C for various times and without 
any additional iodinated ligand. In this way the ligand was allowed to bind to the 
exterior of the cells (remembering that no internalisation occurred at 4°C as was 
confirmed in section 3.3.1) and then its internalisation monitored over a 90 minute 
period at 37°C.
The results of this experiment are shown in Figure 3.4, page 72. As for the previous 
experiments described in section 3.3.1 to 3.3.3, the data plotted represented the mean 
and standard deviation for four wells.
From Figure 3.4, specific binding gradually decreased throughout the entire 90 minute 
period of the 37°C incubation. 60% of the initial ligand bound to the cell-surface had 
disappeared and only 25% of the remaining 40% was internalised. The acid-wash 
values interestingly showed an initial increase from none or a negligible amount of
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^^I-activity internalised into the B16 cells to a maximum at 30 minutes. By 90 
minutes however a third of this (31%) had dissociated from the cells again. This could 
be due to degradation of the ligand or recycling - a question not answered yet. Non­
specific binding as usual, remained relatively low throughout the entire 90 minutes.
To determine what was happening during the 37°C incubation the effect of NH4 Q  
was again introduced into the experiment The same experiment as that shown in 
Figure 3.4 was carried out, in the presence of 20mM NH4 G  and the data is displayed 
in Figure 3.5 on page 73. Again non-specific binding was relatively low throughout the 
experiment. Specific binding was constant between 10 and 90 minutes though there 
was a loss of binding during the first 10 minutes. This initial decrease in binding was 
probably due to desorption. However, the acid-wash data differed to a great extent. 
The 1 2 5I-activity internalised within the cells appeared to increase gradually and was 
still rising at 90 minutes. In fact at 90 minutes, 100% internalisation had occurred, 
shown by the fact that all the specifically bound ligand was now within the cells.
3.3.5 The Effect of Leupeptin on the Internalisation of 
Phe7]a-MSH
Due to the results obtained from the effect of ammonium chloride on the internalisation 
of the ligand (which indicated that degradation could be occurring in the lysosomal 
compartment), leupeptin was introduced into the system. This is a protease inhibitor, 
and its effect would be to inhibit any trypsin-like enzymes in the lysosome from 
functioning properly.
A 10|igml"l concentration of leupeptin was included in the experimental buffers. As for 
NH4 CI, the cells were subjected to a 15 minute pre-incubation at 37°C with leupeptin 
in serum free RPMI1640 medium. All buffers thereafter contained lOjigml*1 leupeptin.
Figure 3.6a on page 74 shows the data obtained for this experiment. There was no 
apparent difference in the internalisation of the ligand when compared to the same 
experiment carried out in the absence of leupeptin (Figure 3.6b, page 75). This may 
indicate that trypsin-like enzymes are not responsible for the breakdown of the 
internalised material.
3.3.6 The Pepstatin A Effect on the Internalisation of [125i_Tyr2}Nle4,D- 
Phe7]a-MSH
Pepstatin A is another protease inhibitor introduced to study its effect on the 
internalisation of the ligand. Pepstatin A has a wider spectrum of use, but inhibits 
aspartic proteases in particular. The same experiment was repeated as in section 3.3.5, 
however, lOiigml' 1 pepstatin replaced the lOjigmH leupeptin.
The results of this experiment are shown in Figure 3.7a and 3.7b on pages 76 and 77 
respectively. As with the leupeptin experiment in section 3.3.5, no apparent differences 
in the internalisation of the ligand was observed. This indicates that the enzymes 
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FIGURE 3.1: 125I Activity after incubation of 0.1 nM [125I-Tyr2,Nle4,D-Phe7]cc-MSH 
with B16 melanoma cells at 4°C with time in a HEPES based buffer, pH 7.4. Each 
point represents the mean ± s.d. from 4 wells. Total (O), specific (▼), non-specific (v) 
binding respectively and internalised ligand (•).
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FIGURE 3.2: 1 2 51 Activity after incubation of O.lnM [125I-Tyr2,Nle4,D-Phe7] a-MSH 
with B16 melanoma cells at 37°C with time in a HEPES based buffer, pH 7.4. Each 
point represents the mean ± s.d. from 4 wells. Total (O), specific (▼), non-specific (•) 
binding respectively and internalised ligand (v).
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FIGURE 3.3: 125I Activity after incubation of O.lnM [125I-Tyr2,Nle4,D-Phe7]a-M SH 
with B16 melanoma cells at 37°C with time in a HEPES based buffer, pH 7.4 in the 
presence of 20mM NH4CI. Each point represents the mean ± s.d. from 4 wells. Total 
(O), specific (▼), non-specific (•) binding respectively and internalised ligand (v).
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FIGURE 3.4: Time dependence on the internalisation of [125I-Tyr2,Nle4,D-Phe7]a- 
MSH into B16 melanoma cells after binding of 0.1 nM of [125I-Tyr2,Nle4,D-Phe7]a- 
MSH to the cell surface for 2 hours at 4°C, followed by incubation at 37°C over a 90 
minute period. Total (o ) , specific (▼), non-specific ( • )  binding respectively and 
internalised ligand (v).
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FIGURE 3.5: Time dependence on the internalisation of 125I-[N le4>D-Phe7]a-M SH 
into B16 melanoma cells after binding of O.lnM of l25i-[Nle4,D-Phe7]a-M SH to the 
cell surface for 2 hours at 4°C, followed by incubation at 37°C over a 90 minute period 
in the presence of 20mM NH4C1. Total (o), specific (▼), non-specific ( • )  binding 
respectively and internalised ligand (v).
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FIGURE 3.6a: Time dependence on the internalisation of 125I-[Nle4,D-Phe7]a-MSH 
into B16 melanoma cells after binding of O.lnM of 12^ I-[Nle4JD-Phe7]a-M SH to the 
cell surface for 2 hours at 4°C, followed by incubation at 37°C over a 90 minute period 
in the presence of lOjigml"1 leupeptin. Total (O), specific (y), non-specific (•) binding 
respectively and internalised ligand (v).
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FIGURE 3.6b: Time dependence on the internalisation of [125l-Tyr2,Nle4,D-Phe7]a- 
MSH into B16 melanoma cells after binding of 0.1 nM of [125I-Tyr2,Nle4,D-Phe7]a- 
MSH to the cell surface for 2 hours at 4°C, followed by incubation at 37°C over a 90 
minute period in the absence of lOfigmT1 leupeptin. Total (O), specific (▼), non­
specific (•) binding respectively and internalised ligand (v).
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FIGURE 3.7a: Time dependence on the internalisation of [125I-Tyr2,Nle4,D-Phe7]a- 
MSH into B16 melanoma cells after binding of 0.1 nM of [125I-Tyr2,Nle4,D-Phe7]a- 
MSH to the cell surface for 2 hours at 4°C, followed by incubation at 37°C over a 90 
minute period in the presence of lOjigml-1 pepstatin A. Total (O), specific ( t ) ,  non­
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FIGURE 3.7b: Time dependence on the internalisation of [125I-Tyr2,Nle4,D-Phe7]oc- 
MSH into B16 melanoma cells after binding of 0.1 nM of [125I-Tyr2,Nle4,D-Phe7]a- 
MSH to the cell surface for 2 hours at 4°C, followed by incubation at 37°C over a 90 
minute period in the absence of lOjigmH pepstatin A. Total (O), specific ( t ) ,  non­
specific (•) binding respectively and internalised ligand (v).
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3.4 DISCUSSION
[Nle4 ,D-Phe7 ]a-MSH has been shown by Sawyer et al (1982), using bioassays, to 
have superagonist potency and an extraordinary prolonged biological activity 
compared with the native hormone, a-MSH. It was resistant to degradative 
inactivation by semm enzymes (Sawyer, T.K. et al; 1980) and hence proved very 
useful for the studies regarding cellular binding and internalisation reported here in 
section 3.3. Previous workers in this area, had suggested binding occurred at the cell 
surface without internalisation (Eberle, A.N. et al; 1977, Legros, F. et al; 1981), 
however the results reported by Panasci et al (1987) challenged this. Panasci and his 
colleagues, although using ND^na-M SH and a FI variant cell-line, found binding and 
internalisation to occur. The results obtained here using [Nle4 »D-Phe7]a-MSH and 
B16 cells are in agreement with these findings.
From the initial experiments performed, it was concluded that internalisation only 
occurred at 37°C and not at 4°C. At 4°C, cellular binding did occur, however, the acid 
treated cells showed a negligible amount of 1 2 5I-activity, implying that no 
internalisation of the [1 2 5I-Tyr2 ,Nle4 ,D-Phe7]a-MSH had occurred. For the 37°C 
experiment, the specific binding and internalised ligand gradually increased from 0  to a 
maximum at 60 minutes. This was followed by a decrease for the remainder of the 
experiment These results agree with the data of Panasci et al (1987) where they used 
an acid-wash to distinguish between extracellularly bound and intracellular associated 
ligand. They too reported a maximum amount of internal ligand at 60 minutes, 
followed by a decrease.
From these results questions arose: the prime question being what causes this decrease 
after 60 minutes? There could be a few reasons for such a pattern, the most likely of 
which was the involvement of degradation. The use of ammonium chloride which acts
as a lysosmotropic agent increasing the pH of the endosomes and lysosomes hence 
restricting lysosomal enzyme degradation and preventing vesicle fusion events in the 
endocytic pathway, (Muller, J-M. et al; 1985) was therefore introduced. A sharp 
difference in the acid treated cells was observed, between those subjected to NH4 Q  
and not subjected to NH4 CI. Instead of reaching a maximum 1 2 5I-activity associated 
with the cells at 60 minutes, after NH4 C1 treatment the radioactivity present was still 
increasing even at 240 minutes, implying that the internalised ligand was still within the 
cells. The specific binding of [l2 5 I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH also continued to 
increase throughout the duration of the experiment. This increase of internalised ligand 
in the presence of ammonium chloride could be accounted for by non-degradation 
resulting in an accumulation, or non-dissociation from internalised receptors trapped 
within the cells.
It should be noted that a second reason for this decrease in activity and apparent loss 
of internalised ligand could be the internalisation of the ligand-receptor complex which 
would ultimately result in a temporary loss of membrane binding sites. A technique 
whereby the receptor could be labelled covalently and then monitored after binding to 
the cell surface would help test this hypothesis.
Although the experiments carried out at 37°C confirmed that internalisation did occur 
for the system of B16 melanoma cells and [1 2 5I-Tyr2 ,Nle4 ,D-Phe7]a-MSH ligand, it 
was not possible to estimate the rate of internalisation with time. Hence, the second 
series of experiments were performed. These introduced the "pulse chase" idea, 
whereby, [12^I-Tyr2 ,Nle4 ,D-Phe7 Ja-MSH was initially bound to the B16 cells at 4°C, 
unbound ligand removed after 2  hours and the cells were then subjected to a 37°C 
incubation. If the ligand still appeared internally, it could then be almost certain that it 
entered the cells via the a-MSH receptor since it was bound to the cell surface 
receptor during the 4°C incubation in the presence of the iodinated ligand.
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The data from such experiments did show the internalisation of [125l-Tyr2 ,Nle4 ,D- 
Phe7] a-MSH. At 0 minutes, no ligand was apparent within the cells but a gradual 
increase occurred up to 30 minutes, after which a decline was observed. The total 
specific association on the other hand, decreased during the whole 90 minutes of the 
incubation at 37°C. These observations were most likely caused by internalisation of 
the surface bound ligand (from the 4°C incubation), and subsequent degradation of the 
ligand or recycling of the receptor-ligand complex.
To probe the phenomenon of degradation, the use of ammonium chloride was again 
introduced. Interestingly, the acid treated cells showed a continuous increase in ligand 
associated with them over the entire 90 minute period of the experiment. The specific- 
binding, was constant between 10 and 90 minutes. Approximately 100% of the 125I 
activity associated with the B16 melanoma cells after 90 minutes appeared to be 
internal. These results further establish the theory that the decreases in cell associated 
activity in the absence of NH4 CI were due to degradation by lysosomal enzymes. So 
overall, the results obtained in the presence of ammonium chloride indicate that the 
decrease in internalised ligand was pH mediated and that it occurred in a relatively 
acidic endocytic environment, such as the lysosome.
As it was considered possible that the decrease in cell-associated activity of the [1 2 5I- 
Tyr2 ,Nle4 ,D-Phe7] a-MSH with the B16 melanoma cells, could be caused by 
degradation occurring in the lysosomal compartment, it was decided to study the 
system with protease inhibitors present. The two inhibitors chosen were leupeptin and 
pepstatin A. Leupeptin inhibits cysteine / serine proteases and is effective at 
micromolar concentrations. Pepstatin A inhibits aspartic proteases and is again 
effective at micromolar concentrations (North, M.J.; 1989). When these were present 
in the experimental set-up, no noticeable difference was observed. Although this may 
imply that the proteases inhibited do not cause the degradation, further work should be
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carried out in this area. In practice there is considerable variation in the concentrations 
of the inhibitors used by different workers and hence, the concentration used in the 
experiments studied here may not be suitable. However, due to the high cost of these 
inhibitors, lOjigmH was the chosen concentration. Harford & Klausner (1987), when 
working with hepatocytes to study receptor-mediated endocytosis, using a 
concentration of lOOjigml' 1 leupeptin, found radioactivity accumulating in lysosomal 
regions of a subcellular fractionation gradient.
Unfortunately there was no available time to further this area of study. In parallel to 
this work however, subcellular fractionation studies were set-up. This was in order to 
achieve a greater insight into the internalisation process and internalisation. The work 
carried out on this area is cited in Chapter 4.




FRACTIONATION OF B16 MELANOMA 
CELLS AND THE FATE OF [1251- 
Tyr2,Nle4,D-Phe7]a-MSH.
4.1 INTRODUCTION
[l25l-Tyr2,Nle4,D-Phe7] a-MSH was internalised after binding to its cell-surface receptor 
was concluded in Chapter 3 from an extensive study involving cell binding experiments 
carried out in well plates. It was determined that after 30 minutes the maximum amount of 
ligand had been internalised, and by 90 minutes the amount of ligand within the cell was 
greatly reduced. From experiments carried out in the presence of ammonium chloride (an 
exogenous amine known to trigger a pH increase in various acidic compartments including 
the lysosome), it was observed that the ligand was still within the cells even as long as 90 
minutes, and indeed was still increasing at this time. These results tend to suggest that the 
ligand is internalised rapidly and is degraded within 30 to 90 minutes after internalisation.
However, it is necessary to study where the ligand travels to once internalised to be able 
to conclude that this is what is actually happening. In order to do this, subcellular 
fractionation experiments were set up. These involved the introduction of density gradient 
centrifugation techniques, where a combination of rate zonal and isopycnic techniques 
were used. Density gradient was chosen over normal differential centrifugation due to its 
permission of analytical measurements to be made, in- addition to complete separation of 
several or all of the components in a mixture. The density gradient method involves a
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supporting column of fluid whose density increases towards the bottom of the tube. The 
density gradient fluid consists of a suitable low molecular weight solute in a solvent in 
which the sample particles can be suspended. In the experiments described below, a 
combination of rate zonal and isopycnic techniques were incorporated whereby the 
gradient was of such a density range that one component sedimented to the bottom of the 
tube, while another component sediments to its isopycnic position and remains there.
Density gradients are used extensively in the separation and purification of a wide variety 
of biological materials. Cells, and cell-particulate fractions including erythrocytes, 
spermatozoa, lymphocytes, bacteria, spleen cells, nerve cells, and the nuclear, 
mitochondrial, microsomal, and supernatant fractions of mammalian tissues have been 
isolated and purified (Bimie, G.D.; 1972; deDuve, C.; 1971). The enzymatic activities 
associated with these fractions, as well as with the less discrete lysosomal and peroxisomal 
fractions, have been measured after density gradient centrifugations.
As was discussed in Chapter 1 of this thesis, sucrose was chosen as the gradient material. 










Table 4.1: Approximate Densities of Macromolecules in Sucrose Solutions.
In theory, the values of density of the plasma membrane (1.16gcm_3) and that of the 
lysosomes (1 .2 1  gem-3) were considered to be different enough to get a clean separation 
after centrifugation. If this were so, then it would then be possible to determine if the 1 2 5I- 
ligand was simply bound to the cell surface (and would therefore be present in the plasma 
membrane fraction) or was within the cells (and migrated to the lysosomal fraction). In 
order to confirm the exact density of these organelles for B16 melanoma cells, enzymes 
assays were set up. For plasma membrane alkaline phosphodiesterse I was chosen to 
determine its position in the sucraose gradient. To locate the lysosomes, P-hexosaminidase 
was used. Details of experimental procedures for these marker enzymes are discussed in 
Chapter 2, section 2.2.4.6, on page 59.
The experiments designed in this case were such as to try and determine the position of 
the ligand once it had undergone internalisation, and if possible calculate the quantity of it 
internalised. As was described in Chapter 2, section 2.2.4.1, extensive work was 
performed on the homogenisation of the B16 melanoma cells in an attempt to optimise the
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disruption of the cells. Severe enough to give adequate separation of the relevant 
organelles, but gentle enough so as not to damage any of them. In addition to this, once 
the separation had been carried out by density gradient centrifugation, the fractions 
associated with plasma membrane or lysosome had to be defined. This was done by 
enzyme assays. Refractive indices were also determined as an indirect measurement of the 
density of each fraction.
Eventually a procedure for subcellular fractionation of B16 murine melanoma cells was 
established. The optimum homogenisation with the equipment available; and fractions 
containing plasma membrane and lysosome were defined.
4.2 METHODS
These are described in detail in Chapter 2.
4.3 RESULTS
4.3.1 Linearity of Sucrose Gradients
The first step in this series of experiments was to establish a method for forming a linear 
sucrose density gradient in a repetitive manner. To do this a number of gradients were 
prepared as described in section 2.2.4.3. These were then subjected to centrifugation, 
35000 RPM at 4°C for 90 minutes, and then fractionated into 200|il fractions. The 
refractive index of these fractions were carried out, and subsequently the density obtained 
from the table displayed in Appendix A.
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A representative graph of density against fraction number is displayed in Figure 4.1 on 
page 93. This clearly shows that a linear gradient between 1.04gcm'3 and 1.20gcm'3 can 
be produced.
This procedure was repeated in the presence of homogenised B16 melanoma cells. Again 
linear gradients were observed , thus confirming that a suitable gradient and centrifugation 
had been established for the fractionation of these cells.
4.3.2 Enzyme Assays
Once a suitable method for forming the gradients had been achieved, it was then essential 
to define the position of the relevant organelles, namely, the plasma membrane and the 
lysosome for the B16 melanoma cells. In order to do this enzyme assays were introduced.
There are certain enzymes characteristic of each subcellular organelle and by assaying each 
fraction of the gradient for a particular one associated with a certain organelle, it could be 
determined at which density the plasma membrane and lysosomes were being separated 
out into. The initial enzymes studied for this purpose were p-glucuronidase (lysosomal 
marker) and 5'-nucleotidase (plasma membrane marker). Unfortunately neither of these 
give the required sensitivity for the fraction size under analysis. Therefore it was necessary 
to look at other marker enzymes which may provide the sensitivity necessary for this 
system. In referance to Muller, J.M. et al (1985), P-hexosaminidase and alkaline 
phosphodiesterase I were next chosen. These were representative of the lysosome and 
plasma membrane respectively. Details of experimental protocols for these assays are 
described in section 2.2.4.6, on page 59.
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The graphs on pages 94 and 95 (Figure 4.2a and 4.2b respectively), represent the enzyme 
marker profiles along the course of the gradient. It must be noted that relative absorbance 
units are stated as a measure of the amount of enzyme within each fraction assayed.
From Figures 4.2a and 4.2b on pages 94 and 95 respectively, it can be concluded that a 
satisfactory method for the enzyme markers assays for the plasma membrane and lysosome 
of B16 melanoma cells had been achieved. It was observed that the plasma membrane 
marker appeared to be predominant in fractions 1 to 6 , however, this was most likely due 
to soluble enzyme either from the cytoplasm or detached during homogenisation. A 
second area of plasma membrane marker occurrence, was between fractions 18 to 2 2  
(density range 1.15 to 1.18gcm"3). For p-hexosaminidase, the major areas of interest 
appear in fractions 14 to 20 (densities 1.16 to 1.18gem-3); the expected density range for 
lysosomes.
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4.3.3 Internalisation of [l25I-Tyr2,Nle4,D-Phe7]a-MSH and its 
Fate once within the Cells Monitored by Subcellular Fractionation 
Studies
In order to determine if B16 melanoma cells could successfully be fractionated and the 
I25j activity associated with each fraction measured, the following experiment was 
performed.
B16 melanoma cells were grown to confluency on 75cm2  Falcon tissue culture flasks. The 
cells were subjected to a 2 hour incubation at 4°C or a 30 minute incubation at 37°C in 
O.lnM [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH. This was carried out in the presence and absence 
of 1 0 0 0 -fold excess non-iodinated ligand, and parallel flasks were set up to determine the 
extent of internalisation (by the acid washing technique previously used for the cell well 
experiments). At the end of the incubation, the unbound ligand was discarded and the cells 
thoroughly washed with ice-cold serum free RPMI 1640 medium. The cells were then 
scraped from the flasks and homogenised, centrifuged and fractionated as described in 
sections 2.2.4.1 and 2.2.4.2.
The graphs displayed in Figures 4.3 and 4.4 represent the fractionation of B16 cells 
subjected to a 4°C and 37°C incubation respectively. The 4°C data (Figure 4.3, page 96) 
relates favourably with that obtained with the cell well experiments in that no 
internalisation has apparently occurred. The activity associated with the fractionated cells 
appears in the initial fractions of the sucrose gradient, those where the plasma membrane 
predominates. Note there is a small peak at fraction 20, possibly due to trapping of the 
plasma membrane, or too severe a homogenisation. Little or no 125I activity is observed 
internally in later and more dense fractions associated with intracellular organelles. In 
contrast Figure 4.4, on page 97, the repeat experiment at 37°C shows a different profile of
radioactivity associated with each fraction. In this case, the 125I appears to be more 
pronounced in a more dense region of the gradient (fractions 16 and above). In 
comparison with figure 4.3, the acid-resistant 12^ I activity is more defined with a peak 
around fractions 16 to 2 1 , those known to be associated with internal organelles, 
lysosomes included. No such peak of activity was observed for the 4°C experiment.
The results obtained from this experiment would tend to suggest that separation of the 
organelles has been achieved to a degree high enough to allow observation of internalised 
ligand and that associated with the exterior of the cells. The acid treated cells display no 
internalisation at 4°C, that is, no 125I activity associated with the lysosomes and at 37°C 
the opposite occurs.
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4.3.4 Time Course Experiment of [125I-Tyr2,Nle4,D-Phe7]a-MSH 
to Follow the Fate of the Internalised Ligand Using Sucrose 
Density Gradient Subcellular Fractionation
From the results obtained in section 4.3.3 above, separation of internalised and surface- 
bound [1 25l-Tyr2 ,Nle4 J3-Phe7 ]a-MSH was successfully accomplished by subcellular 
fractionation. A series of experiments were then designed to follow the path of the ligand 
after binding at 4°C. These were similar to the "pulse chase" experiments described in 
section 3.3.4. Cells were grown to confluency on 75cm2  Falcon tissue flasks and 
incubated for 2 hours at 4°C in O.lnM [12 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH. After washing 
with serum free RPMI 1640 medium, they were subjected to a second incubation at 37°C 
in serum free RPMI 1640 media in the absence of any iodinated material. At the end of the 
required time at 37°C the cells were scraped from the flasks and fractionated as described 
earlier (section 2.2.4.1 to 2.2.4.3).
The graphs displaying the data obtained for this study are shown on pages 98 to 101. 
Figure 4.5a represents the profile of radioactivity observed for no incubation at 37°C, that 
is to say it shows what happened after the 4°C incubation. Although a high peak of 125I 
activity was observed at the beginning of the gradient this was not thought to represent 
intact plasma membrane. It was the peak around 16 to 22 which was of greater interest, 
which represented the denser ffigement. When an acid wash had been carried out no such 
peak was observed suggesting any [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH bound to the 
melanoma cells was surface bound and could be removed by the acid wash treatment.For 
the next two timepoints, the 15 minute and 30 minute incubations at 37°C, figures 4.5b
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and 4.5c respectively, the major observation was the failure of the acid wash to remove 
the peak of 12^ I activity in the denser fractions. This would indicate that at these times the 
ligand had moved from the outer surface of the cell inwards. Interestingly, the 60 minute 
timepoint (figure 4.5d) showed a highly reduced amount of 125I activity, and no defined 
areas of increased activity. This would imply that by 60 minutes at 37°C the ligand had 
either left the cells or had been degraded.
To confirm if degradation was occurring, the use of NH4 CI was again introduced as had 
been in the cell well experiments. The same experiment as above was repeated, but in the 
presence of 20mM NH4 C1. The results are displayed in Figure 4.6a-d on pages 102 to 
105.
As in the experiment shown in Figure 4.5a-4.5d, the graphs labelled a, b, c and d are for 0, 
15, 30 and 60 minutes incubation at 371°C respectively. As in figure 4.5a, the experiment 
carried out in the absence of NH4 CI, figure4.6a representing the same experiment but in 
the presence of NH4 C all peaks of 12^ I activity shown to be associated with the cells are 
removed in the presence of an acid wash indicating once again that at 4°C, all the 125I 
associated with the B16 melanoma cells was extracellularly bound. For the 15 minute and 
30 minute timepoints ( figures 4.6b and 4.6c respectively) very similar results were 
obtained as for the equivalent timepoints in the absence of the NH4 CI (figures 4.5b and 
4.5c). Not all the 125I associated with the cells was removed by an acid wash again , 
indicating the transfer of surface bound ligand to the inside of the cells. The 60 minute 
timepoint ( figure 4.6d) showed clearly the effect of NH4C1. Unlike figure 4.5d where a 
wide spread of low 1251 activity was observed, there was an abundant peak of 1251 
activity associated with the cells, not all of which was removed by an acid wash. This
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would indeed further suggest that the lysosome was in some way connected with the 
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FIGURE 4.3: 125I-activity associated with each sucrose fraction for cells incubated for 2 
hours at 4°C with 0.1 nM [12^I-Tyr2,Nle4JD-Phe7]a-MSH prior to homogenisation and 
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FIGURE 4.4: 1251-activity associated with each sucrose fraction for cells incubated for 30 
minutes at 37°C with O.lnM [125I-Tyr2,Nle4,D-Phe7]a-M SH prior to homogenisation and 













FIGURE 4.5a: 125I-activity associated with each sucrose fraction for cells incubated for 2 
hours at 4°C with O.lnM [125I-Tyr2,Nle4,D-Phe7]a-MSH prior to homogenisation and 
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FIGURE 4.5b: 125I-activity associated with each sucrose fraction for cells incubated for 
2 hours at 4°C with 0.1 nM [125I-Tyr2,Nle4J0-Phe7]a-MSH, followed by incubation at 37 
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FIGURE 4.5c: 125I-activity associated with each sucrose fraction for cells incubated for 2 
hours at 4°C with O.lnM [125I-Tyr2,Nle4,D-Phe7]a-MSH, followed by incubation at 37° 
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FIGURE 4.5d: 125I-activity associated with each sucrose fraction for cells incubated for 
2 hours at 4°C with 0.1 nM [125I-Tyr2,Nle4,D-Phe7]a-MSH, followed by incubation at 37 
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FIGURE 4.6a: 125I-activity associated with each sucrose fraction for cells incubated for 2 
hours at 4°C with O.lnM [125I-Tyr2,Nle4,D-Phe7]a-MSH prior to homogenisation and 
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FIGURE 4.6b: 125I-activity associated with each sucrose fraction for cells incubated for 
2 hours at 4°C  with O.lnM  [ 125I-Tyr2,Nle4J0-Phe7]a-M S H , followed by incubation at 37 
°C for 15 m inutes prior to hom ogenisation and fractionation in the presence of 20mM 
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FIGURE 4.6c: 125I-activity associated with each sucrose fraction for cells incubated for 2 
hours at 4°C with O.lnM [125I-Tyr2,Nle4J)-Phe7]a-MSH, followed by incubation at 37° 
C for 30 minutes prior to homogenisation and fractionation in the presence of 20mM 
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FIGURE 4.6d: 125I-activity associated with each sucrose fraction for cells incubated for 
2 hours at 4°C with O.lnM [125I-Tyr2, Nle4,D-Phe7]a-MSH, followed by incubation at 37 
°C for 60 minutes prior to homogenisation and fractionation in the presence of 20mM 
NH4CL Total binding ( ) and internalised ligand ( ).
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4.4 DISCUSSION
The work studied in Chapter 3 dealt with the cellular binding and uptake of the a-MSH 
superpotent analogue, [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH. Data obtained confirmed the 
specific binding of ligand at 4°C and 37°C. In addition, at 37°C, a marked amount of 
ligand was shown to be internalised, as was apparent from the acid wash data obtained. 
Moreover, the introduction of NH4 CI, an exogenous amine, implied that once internalised 
the ligand makes its way to the lysosomal compartment prior to degradation or recycling.
In an attempt to observe that the ligand does travel to the lysosome, the subcellular 
fractionation of the B16 melanoma cells was performed. Due to the fact that very little 
work has been done concerning this area, it was necessary to start from the beginning and 
set up homogenisation, centrifugation and fractionation assays.
The initial step was to find a suitable homogenisation method suitable for disrupting the 
B16 melanoma cells; enough to allow separation of their subcellular components, but 
gentle enough to ensure the separated components remained intact. Too severe a 
disruption would cause breakage of the membranes of the internal components of the cells 
and would be of no use for these studies. A detailed explanation of the development of a 
suitable homogenisation protocol is given in section 2.2.4.1, page 51.
It was decided to concentrate on isolating the plasma membrane and lysosome. The reason 
being, at 4°C, from cell binding experiments described in chapter 3, binding occurs only at 
the cell surface without internalisation and hence, would only be observed in the plasma 
membrane fractions isolated. In comparison, at 37°C, it would be expected to observe 
increased activity in lysosomal fractions prior to the ligand leaving the cells. To define the 
individual components of plasma membrane and lysosome, enzyme marker assays were
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individual components of plasma membrane and lysosome, enzyme marker assays were 
introduced. |3-Hexosaminidase was chosen as the lysosomal marker and alkaline 
phosphodiesterase I as the plasma membrane marker (Muller, J.M. et al; 1985).
In order to determine if this sucrose gradient fractionation technique could discriminate 
between internalised ligand and extracellularly bound ligand, experiments were carried out 
at 4°C and 37°C. The data from such experiments did show that the iodinated ligand was 
eliminated by an acid wash for the 4°C experiment (figure 4.3), whereas, at 37°C (figure 
4.4) ther was still 125I activity associated with the heavier fractions of the sucrose 
gradient. The high level of 125I activity present at low densities for the 4°C experiment 
could be explained by "free 12 5 I", that is, iodinated peptide which freed itself from the 
receptor; or it could be very small fragments of plasma membrane which exhibit low 
density.
Although these experiments indicated that a distinct separation of the plasma membrane 
and lysosome fractions could not be achieved using this procedure, they suggest that the 
fate of the ligands could be qualitatively determined. Therfore, a series of "pulse chase" 
time course experiments were designed with the major aim being to further confirm the 
internalisation of the ligand and trafficking to internal organelles including the lysosome.
The first series of time course experiments were carried out by bonding of the ligand for 2 
hours at 4C, followed by 1, 15, 30 and 60 minutes at 37°C. For the cells incubated only at 
4°C a peak of activity was observed between fractions 16 and 21. In the presence of an 
acid wash this was not observed indicating that that observed for total binding was 
associated with the plasma membrane. A similar observation was found for cells incubated 
at 37°C for 15 minutes after 2 hours at 4°C. This time however, not all the 125I activity 
was removed when treated with an acid wash. A small "peak" of activity was observed
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between fractions 16 and 20. For the third timepoint in this experiment (30 minutes at 37° 
C), a similar trace of activity was found as for the 15 minute time period. When the cells 
had been incubated for 60 minutes at 37°C, there was very little 125I activity associated 
with the cells and no distinct areas containing higher levels of ligand were observed.
In comparison to this, the same experiment was performed but in the presence of 20mM 
NH4 CI. The major difference was observed when the cells were incubated for 60 minutes 
at 37°C (figure 4.6d). A large area of 125I activity was observed in fractions of higher 
density for both the acid washed data and total 125I activity. Note, for the equivalent 
timepoint in the absence of NH4 CI, no such peaks of activity were found. These data 
further imply that once the ligand has bound to the cell surface (plasma membrane), it 
moves inside the cell to intracellular organelles, probably the lysosome where degradation 
may occur.
In order to prove that degradation does occur, an experiment whereby the intactness of 
the ligand could be measured needs to be investigated. One way of doing this would be to 
prepare fragments of the ligand and determine their elution position using FPLC in 
conjunction with column chromatography techniques. Then, to determine if degradation 
has occurred, samples of the digested cells and the medium in which they have been 
incubating could be passed through the system and the elution of the fractions monitored. 
The appearance of degraded fragments would be observed if indeed, degradation is 
occurring. Panasci and his colleagues (1987), studying the metabolic fate of tritriated Ac- 
[Nle4 J)-Phe7 ]a-MSH4 _11NH4  with the FI variant of B16 melanoma cells, made use of a 
30cm column of Sephadex G-10 to monitor the degradation (Panasci, L.C. et al; 1987). 
They concluded the appearance of an intermediate degradation product at 4 hours of a 
cellular sample and furthermore, analysis of a 2 hour dissociation of a 30 minute
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cellular sample revealed that the majority of the radioactivity eluted in the same position as 
leucine.
In conclusion then it can be said that the results obtained from subcellular fractionation 
studies further confirm internalisation of the ligand. They also support the theory that the 
lysosome has a major role (possibly degradation) in the decrease of activity associated 
with the B16 melanoma cells after 30 minutes.
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CHAPTER 5
The Effect of Size of Ligand on the 
Internalisation of Analogues into B16 
Melanoma Cells.
5.1 INTRODUCTION
If peptides can be used to target drugs specifically to their site of action, it is not just 
enough for the hormone itself to reach its required site and be internalised in order to 
fulfil its role. A drug molecule must also be able to reach the cell site and be internalised. 
The previous two chapters concluded that the [1 2 5I-Tyr2 ,Nle4 ,D-Phe7] a-MSH analogue 
did bind specifically to an a-MSH receptor and was rapidly internalised into the B16 
melanoma cells. Subcellular fractionation studies implied the ligand once within the cells, 
travelled to the lysosomal regions where upon it was degraded or recycled. However, 
[l25j_Tyr2,Nle4,D-Phe7] a-MSH is a small molecule and it would be of great interest to 
study larger ligands and observe how they bind, and/or are internalised into the B16 
melanoma cells. To do this, Na-biotin-[Nle4 ,D-Phe7]a-MSH and streptavidin-biotin- 
[Nle4 JD-Phe] a-MSH were studied. These are two ligands of increasing molecular weight 




These are described in detail in Chapter 2.
5.3 RESULTS
5.3.1 Internalisation of Na-Biotin-[l25I-Tyr2,Nle4,D-Phe7]a-MSH 
into B16 Melanoma Cells at 37°C
N«-Biotin-[1 2 5 I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH (O.lnM), was bound to 5  x 105  B16 
melanoma cells in a 24-well tissue culture plate for 2 hours at 4°C in the absence or 
presence of 1000-fold non-iodinated ligand. Unbound ligand was then removed and the 
cells were subjected to a second incubation at 37°C for various periods of time. The 
amount of activity associated with the cells specifically, non-specifically and internally was 
monitored as for [1 2 5I-Tyr2 ,Nle4 ,D-Phe7] a-MSH as reported in Chapter 3. As normal, the 
data displayed is the mean and standard deviation of four wells.
Figure 5.1 on page 114, represents the "pulse chase" internalisation of Na -Biotin-[125i_ 
Tyr2,Nle4 JD-Phe7 ]a-MSH. Specific binding was found to decrease gradually over the 90 
minute period of incubation at 37°C, as was found with [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH 
(The data for which is as displayed in figure 5.7, page 120). In agreement with the [1 2 5I- 
Tyr2 ,Nle4 ,D-Phe7 ]a-MSH, the amount of internalised ligand increased to a maximum at 
30 minutes and then decreased gradually over the remaining 60 minutes of the experiment 
It must be noted that a lesser amount of Na-biotin-[Nle4 ,D-Phe7 ]a-MSH appeared to 
degrade or leave the cells in comparison to the [Nle4 ,D-Phe7 ]a-MSH ligand.
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The experiment was repeated in the presence of 20mM NH4 CI to observe the effect of the 
exogenous amine on the internalisation rate of the larger ligand. It was of interest to 
determine if the same effect would be apparent as was for the [12^I-Tyr2 ,Nle4 ,D-Phe7 ]a- 
MSH. Figures 5.2 and 5.8 (pages 115 and 121 respectively) display the data obtained for 
each ligand. A similar trend was obtained for the Na-biotin- [12 5 I-Tyr2 ,Nle4 ,D-Phe7] a- 
MSH has had been obtained for [12^I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH. Specific binding 
gradually decreased throughout the 37°C incubation, whereas, the internalised ligand was 
found to increase over the same time period. However, for the Na-biotin-[1 2 5I- 
Tyr2 ,Nle4 ,D-Phe7] a-MSH, the amount of ligand associated with the cells was still 
increasing at 90 minutes and in fact 6 6 % of that associated specifically was internally 
associated. This was in comparison to almost 100% of the [12 5I-Tyr2 ,Nle4 ,D-Phe7 ]a- 
MSH being internalised at the equivalent time period, that is, at 90 minutes all ligand 
specifically bound was internalised. These results would tend to suggest internalisation 
does occur for the larger ligand and degradation or recycling also appears to happen, but 
at a slower rate.
5.3.2 Internalisation of Streptavidin-Biotin-[125I-Tyr2,Nle4,D- 
Phe7]a-MSH into B16 Melanoma Cells at 37°C
The addition of streptavidin to the Na-biotin-[Nle4 ,D-Phe7 ]a-MSH ligand to increase the 
size of the ligand even further was next studied. The results obtained regarding the time 
course internalisation of the streptavidin ligand are shown in figures 5.3 and 5.4, on pages 
116 and 117 in the absence and presence of 20mM NH4 CI respectively.
The trend of binding and internalisation varies from that obtained for both the [1 2 5I- 
Tyr2 ,Nle4 ,D-Phe7 ]a-MSH and biotin-[1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH for this analogue.
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As figure 5.3 shows the specific binding of the streptavidin-biotin-[1 2 5I-Tyr2 ,Nle4 ,D-Phe7] 
a-MSH appears to decrease quite rapidly. In addition, the ligand although internalised, 
does so more slowly than for the previous ligands tested. Even at 90 minutes the ligand 
appeared to still be internalising. In other words, no maximum point of intracellular 
accumulation at 30 minutes (as had been apparent for the other ligands) was found to 
occur. Due to this observation, a further experiment was carried out in which the final 
time point for the measurement of internalisation was extended from 90 minutes to 240 
minutes for the 37°C incubation. The data from this experiment is displayed in figures 5.5 
and 5.6 on page 118 and 119 respectively. This time the familiar pattern of increasing 
internalisation to a specific time point, followed by a gradual decrease to the end of the 
experiment is observed. For streptavidin-biotin-[Nle4 ,D-Phe7] a-MSH, the maximum 
amount of ligand within the cells was apparent at 90 minutes, followed by a gradual 
decline to the end of the 240 minute period.
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FIGURE 5.1: Time dependence on the internalisation of Na -Biotin-[12^ I-Tyr2,Nle4,D- 
Phe7]a-MSH into B16 melanoma cells after binding of O.lnM Na -Biotin-[125I- 
Tyr2,Nle4JD-Phe7]a-MSH to the cell surface for 2 hours at 4°C, followed by incubation at 
37°C over a 90 minute period. Total (O), specific (▼), non-specific (•) binding respectively 
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FIGURE 5.2: Time dependence on the internalisation of Na-Biotin-[125I-Tyr2,Nle4,D- 
Phe7]a-MSH into B16 melanorAa cells after binding of O.lnM Na -Biotin-[125I- 
Tyr2,Nle4JD-Phe7]a-MSH to the cell surface for 2 hours at 4°C, followed by incubation at 
37°C over a 90 minute period in the presence of 20mM NH4C1. Total (o), specific (▼), 
non-specific (•) binding respectively and internalised ligand (v).
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F IG U R E  5.3: Time dependence on the internalisation o f Streptavidin-Biotin-[125I- 
Tyr2 ,Nle4 ,D -Phe7]a-M SH  into B16 melanoma cells after binding o f O.lnM  Streptavidin- 
B iotin-[125I-Tyr2, Nle4 ,D-Phe7]a -M S H  to the cell surface for 2 hours at 4°C, followed by 
incubation at 37°C over a 90 minute period. Total (O ), specific (▼), non-specific ( • )  
binding respectively and internalised ligand (v).
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FIG U R E  5.4: Time dependence on the internalisation o f Streptavidin-B iotin-[12^I- 
Tyr2,Nle4 ,D -Phe7]a -M S H  into B16 melanoma cells after binding o f O .lnM  Streptavidin- 
Biotin-[125I-T yr2,Nle4 ,D-Phe7] a -M S H  to the cell surface for 2 hours at 4°C , followed by 
incubation at 37°C over a 90 minute period in the presence o f 20mM NH4CL Total (O), 
specific (▼), non-specific (•) binding respectively and internalised ligand (v).
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FIGURE 5.5: Time dependence on the internalisation o f Streptavidin-B iotin-[12^I- 
Tyr2,Nle4,D-Phe7] a-M SH  into B16 melanoma cells after binding o f O .lnM  Streptavidin- 
B iotin-[125I-Tyr2,Nle4,D-Phe7]a-M S H  to the cell surface for 2 hours at 4°C, followed by 
incubation at 37°C over a 240 minute period. Total ( o ) ,  specific (▼), non-specific ( • )  
binding respectively and internalised ligand (v).
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FIGURE 5.6: Time dependence on the internalisation of Streptavidin-Biotin-[125I- 
Tyr2,Nle4,D-Phe7]a-M SH into B16 melanoma cells after binding of O.lnM Streptavidin- 
Biotin-[125I-Tyr2,Nle4JD-Phe7]a-M SH to the cell surface for 2 hours at 4°C, followed by 
incubation at 37°C over a 240 minute period in the presence of 20mM NH4CI. Total (O), 
specific (y), non-specific (#) binding respectively and internalised ligand (v).
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FIGURE 5.7: Time dependence on the internalisation of [125I-Tyr2,Nle4,D-Phe7] a-MSH 
into B16 melanoma cells after binding of O.lnM [125I-Tyr2,Nle4,D-Phe7]a-MSH to the 
cell surface for 2 hours at 4°C, followed by incubadon at 37°C over a 90 minute period. 
Total (o), specific (▼), non-specific (•) binding respectively and internalised ligand (v).
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FIGURE 5.8: Time dependence on the internalisation of [125I-Tyr2,Nle4,D-Phe7]a-M SH 
into B16 melanoma cells after binding of O.lnM [125I-Tyr2,Nle4,D-Phe7]a-MSH to the 
cell surface for 2 hours at 4°C, followed by incubation at 37°C over a 90 minute period in 
the presence of 20mM NH4C1. Total (O), specific (▼), non-specific (•) binding respectively 
and internalised ligand (v).
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5.4 DISCUSSION
As mentioned in the introduction of this chapter, it is not just enough for the Ac-[Nle4 ,D- 
Phe7 ]a-MSH to be shown to be internalised via the a-MSH receptor of B16 melanoma 
cells, if such a system has the potential in drug targeting of cytotoxic drugs to their 
specific sites of action. The drugs which would be required are of much larger molecular 
weight and without a comparison with larger molecules, no direct evidence that the system 
proposed in this study would be of any use whatsoever. Not only that but it may be 
necessary for these larger drugs to be internalised to actually have the desired effect 
Hence, it was necessary to try and "mimic" attachment of a drug to the parent analogue, 
Ac-[Nle4 ,D-Phe7] a-MSH. Unfortunately, no such drug-peptide molecules were available 
for use at the time, however, the use of the analogues Na-biotin-[Nle4 ,D-Phe7 ]a-MSH 
and streptavidin-biotin-[Nle4 ,D-Phe7 ]a-MSH were introduced.
The data obtained from the cell well experiments suggest that internalisation of both the 
larger analogues was found to occur. This appeared to be in an efficient manner. Specific 
binding occurred for both analogues, although that for the streptavidin-biotin-[Nle4 ,D- 
Phe7] a-MSH appeared smaller than for the other two analogues. This was most probably 
due to the size of the added streptavidin portion which may interfere with the ability of the 
peptide to bind with the a-MSH receptor and be subsequently internalised. The acid wash 
results did show confirmation of internalisation for both the Na-biotin-[Nle4 ,D-Phe7 ]a- 
MSH and streptavidin-biotin-[Nle4 ,D-Phe7 ]a-MSH ligands. For both however, the rate of 
internalisation was found to be less than for [ 1 2 5I-Tyr2 ,Nle4 ,D-Phe7] a-MSH. As far as 
streptavidin-biotin-[Nle4 ,D-Phe7 ]a-MSH was concerned a longer time period of 240
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minutes, compared with the normal 90 minutes, was needed to observe the familiar pattern 
of internalisation.
In conclusion, it can be said that internalisation of the larger peptide molecules was indeed 
found to occur. Even though the system may not be as efficient as for smaller analogues, 
the fact that the larger molecules appeared to move inside the cells after their initial 
surface binding, indicates the feasibility of the use of the a-MSH receptor as a means of 
targeting drugs too and inside the melanoma cells. In fact, Richards, A.C. (1992), working 
in the same laboratory at the University of Bath, has confirmed the internalisation of a 
methotrexate-conjugate into B16 melanoma cells.
As far as what happened to the ligands once they were internalised, the experiments 
containing NH4 CI (the exogenous amine which raises the pH of the lysosomes, hence, 
resulting in no degradation) were again performed for these larger sized molecules. The 
results obtained implied that once the ligand found itself inside the cells, they behaved in a 
manner similar to Ac-[Nle4 ,D-Phe7] a-MSH. That is to say, no decrease after 30 minutes 
and after 90 minutes for Na-biotin-[Nle4 ,D-Phe7 ]a-MSH and streptavidin-biotin-[Nle4 ,D- 
Phe7 ]a-MSH respectively, was observed, when 20mM NH4 CI was present in the cell 
system. Again, these results tend to favour the conclusion that the decrease found to occur 
after a certain time period could be due to degradation of the internalised ligand, or 
receptor-ligand complex, in the lysosomal compartment of the cells. As was discussed in 
chapter 4 when dealing with the fate of Ac-[Nle4 ,D-Phe7] a-MSH after its internalisation, 
a further set of experiments are needed. These would be designed in such a way as to 
determine the degraded fragments of the analogues. Initially a series of fragments likely to 
occur once the ligand has undergone degradation would be prepared using peptide 
synthesis techniques. Following iodination of these fragments they would then be passed 
through a column and their elution time noted. Then to determine the degradation
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products from the cell system, the cell homogenate, and/or the medium the cells were 
incubated in would be passed through the same column and the elution times of products 
monitored.
Overall, as far as the larger molecules and their behaviour is concerned with the B16 
murine melanoma cells studied here, it is suffice to say that internalisation does occur, 
even though possibly at a reduced rate as the size increases. Hence, the future potential of 
the use of this peptide targeting system of a-MSH analogues would appear to be 




The major aim of drug targeting, or site specific drug delivery, is to selectively deliver 
therapeutic agents to the desired site of action. If this criteria is fulfilled then, not only will 
the therapeutic effectiveness of the drug be increased dramatically, but also, there will be a 
vast decrease in the toxic side effects often associated with drugs. Unfortunately, such a 
process is not simple due to the complexities of the human body. More often than not, 
drugs prescribed for one disease can, due to lack of specificity, cause damage to normal 
cells or tissues, and in effect may cause more harm then there already is. Due to this 
inability of getting drugs to the site of disease accurately and without harming surrounding 
areas, the concept of site specific drug delivery was introduced.
The basic principle of site specific drug delivery is to find some way of getting the drug 
from its site of entry into the body, to the diseased area and nowhere else within the body. 
Such an achievement would not only cancel out damaging undiseased cells/tissues, but, 
would also lengthen the life time of the drug, or in other words, decrease the degradation 
and premature excretion of the drug before it has carried out its desired effect.
Although a major hurdle would have been overcome if one could successfully do this, and 
actually transport the drug to the site of action only and in a therapeutic form, there is then 
the question of how does the drug actually carry out its action? For the majority of drugs, 
this does not just involve transporting the drug to the damaged cell, but, it usually relies 
on the drug entering the cell and being capable of giving the desired effect once inside the 
cell. Thus it is very much apparent the complexities involved in drug targeting. Not only
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does the human body cause severe problems in allowing the drug to reach its "goal", the 
diseased cells, but, then the cells themselves must contain certain molecular moieties 
which will allow the entry of the drug or drug/carrier.
As far as peptides are concerned, such a process is carried out by a receptor. Receptors 
are functionally linked to an effector system that is triggered upon agonist (ligand) 
binding. Being in most instances a membranal system, we must consider the receptor- 
effector system as a transmembrane signalling system, where the receptor faces the outside 
of the cell and the effector faces the intracellular space. The number of carrier-ligand 
receptors expressed on the target cell as well as the distribution of such receptors in other 
cells and tissues are important parameters which need to be considered in selecting a 
particular ligand as a carrier (Shen, W-C, et al; 1992). In general, the pharmacological 
effects of drugs are determined by many factors including:-
1. Receptor binding.
2. Cellular internalisation.
3. Intracellular sorting and targeting.
4. Intracellular transport.
The ligand predominantly employed in this study was the superpotent analogue of a- 
MSH, [Nle4 ,D-Phe7] a-MSH. It was radiolabelled and the mono-iodinated form used in all 
experiments performed in this study. The choice of cellular system used in conjunction 
with this analogue, were the B16 murine melanoma cell line. It had been established by 
Solca, F and his colleagues (1989), that a a-MSH receptor does exist. They synthesised a 
potent a-MSH photolabel, 1 2 5I-Naps-MSH and applied it to mouse and melanoma cells; 
they characterised a 45kDa protein of B16-F1 cell membrane. Therefore, the system used
126
in this study was such that a receptor for a-MSH and its analogues was known to exist, 
and a suitable, superpotent probe, [Nle4 ,D-Phe7] a-MSH was available for use.
Before initiation of this study, it had already been established in our laboratory, that [1 2 5I- 
Tyr2 -Nle4 ,D-Phe7] a-MSH displayed specific binding of 0.37-0.87nM. It was also 
known that only 4000-5000 binding sites per B16 cell were available (Erskine, M.E; 
unpublished results). So although it had been confirmed that [1 2 5I-Tyr2 -Nle4 ,D-Phe7 ]a- 
MSH elicits its biological action through binding to the MSH-membrane receptor, it was 
unknown whether or not internalisation of the receptor/ligand occurred. Hence, the initial 
experiments were designed so as to establish such a point.
It has been observed in a number of ligand-receptor systems that surface-bound 
radioligand can be dissociated by lowering extracellular pH. In these situations the fraction 
of total cell-associated binding removed by acid-exposure of cells is interpreted to 
represent surface-accessible binding. Hence, any activity associated with the cells after 
acid treatment represents internalised ligand. The validity of using reduced pH to 
dissociate ligand from receptors at the cell surface and thus distinguish surface-bound 
from internalised radioligand has been confirmed by Carpenter and Cohen (1976), by 
performing studies using quantitative electron microscopy radiography.
The acid wash procedure developed for the study of [1 2 5I-Tyr2 -Nle4 ,D-Phe7] a-MSH 
internalisation into B16 melanoma cells, was 0.1M citrate buffer, consisting of citric acid, 
sodium chloride and 1M NaOH to give a working pH of 2.5. Work not reported in this 
study, but which was carried out, showed that a pH of 2.5 was necessary to remove cell 
surface bound ligand, both in the cell binding experiments and cell fractionation studies.
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To prove the phenomenon of internalisation in the system chosen for this study, initial 
experiments were carried out whereby, binding of [1 2 5I-Tyr2 -Nle4 ,D-Phe7 ]a-MSH was 
allowed to bind to B16 melanoma cells either in the presence or absence of excess 
unlabelled ligand both at 4°C and 37°C. In addition, binding of the ligand followed by an 
acid wash was included. At 4°C, binding was shown to be increasing over a 4 hour period. 
The acid treated cells, on the other hand, displayed very little 125I activity, suggesting no 
internalisation was occurring at this temperature. For the same experiment performed at 
37°C, acid-resistant 125I activity was apparent. The profile of 125I activity over a 4 hour 
period, displayed maximum internalised ligand at 60 minutes followed by a gradual 
decrease. Unfortunately, no way of assaying the 125I activity was available in order to 
determine the chemical state of the radioactivity. The decrease in internalised ligand after 
60 minutes could be due to degradation. However, to confirm such a fact, 
chromatographic techniques are needed which can identify the [1 2 5I-Tyr2 -Nle4 ,D-Phe7]oc- 
MSH in an intact state, and also fragments of the peptide.
Although it was not possible to ascertain whether the 125I activity associated internally 
was associated with [1 2 5I-Tyr2 -Nle4 ,D-Phe7 ]oc-MSH, or more likely, in a degraded form, 
some insight into what was happening after internalisation could be achieved by the 
lyosomotropic agent by increasing the pH of the endosome and lysosomal compartments, 
hence restricting lysosomal degradation and preventing vesicle fusion events in the 
endocytic pathway. Inclusion of 20mM NH4 C1 into the system had a very dramatic effect 
on the internalised ligand. No peak level of acid-resistant 125I activity was observed. 
Instead, the amount of 125I activity associated with the cells over a 4 hour period at 37° 
C, was shown to be continually increasing. At 4 hours, the amount of ligand (12^ I activity) 
associated with the B16 cells, appeared to be internalised. The conclusions drawn from 
such a study are that degradation is the most probable reason for the decrease in 125I 
activity within the cells after 60 minutes. By the inclusion of NH4 CI, this decrease is not
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present and since NH4 CI is an inhibitor of lysosomal degradation, it would appear to be 
valid to suppose that degradation of the [1 2 5I-Tyr2 -Nle4 ,D-Phe7 ]a-MSH is the main cause 
for the decrease in acid-resistant 1 2 5I-activity associated with the B16 melanoma cells.
To summarise the results so far, it can be said that internalisation of [1 2 5I-Tyr2 -Nle4 ,D- 
Phe7] a-MSH does indeed occur. Moreover, some insight into what may happen once 
internalised has been obtained with the work carried out in the presence of the exogenous 
amine, ammonium chloride.
Despite the fact that confirmation of internalisation has been determined, it would now be 
reasonable to surmise the use of the a-MSH receptor in the role of internalisation of the 
ligand. Therefore, a series of experiments were designed whereby the ligand was exposed 
to the cells for 2 hours at 4°C (i.e. no internalisation was permitted, only cell surface 
binding) and upon removal of excess iodinated ligand not bound to the cells, the cells were 
incubated at 37°C for further time periods. It was assumed that during the 4°C incubation, 
[l2 5 I-Tyr2 -Nle4 ,D-Phe7 ]a-MSH was able to bind to the a-MSH receptor at the cell 
surface. Then during the 37°C incubation, this would be internalised via the a-MSH 
receptor. If internalisation was observed then it would be implied that the receptor was 
responsible for such a process and receptor-mediated endocytosis had occurred. In 
addition, such a set of experiments would illustrate the time-course of the internalisation 
process in more detail.
The outcome of these experiments suggested that the a-MSH receptor was employed in 
the transfer of externally bound ligand on the cell surface, to the inside of the cells. 
Internalised, or acid-resistant, 125I activity was immediately present once the cells were 
transferred to 37°C. Moreover, a maximum amount of iodinated ligand was measured 30 
minutes after the cells had been transferred to the 37°C incubator, longer periods of
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incubation displayed decreased levels of acid-resistant 125I activity with the cells. In 
conjunction with this observation, the amount of ligand bound specifically to the cells was 
seen to decrease gradually throughout the entire 90 minute period of the 37°C incubation. 
It can be suggested that, since the bound ligand decreases in parallel with an increase of 
ligand inside the cells, the iodinated ligand initially bound to the cell surface a-MSH 
receptor is transported into the cells at metabolic temperature (37°C).
As previously observed, there was a maximum amount of internalised activity observed, 
followed by a gradual decrease. So, as for the previous experiments, ammonium chloride 
was introduced into the system and again this "peak” of activity was avoided. Instead, the 
internalised activity continued to increase for the whole 90 minute period of the 
experiment This further confirms that degradation occurs after the ligand is within the 
cells, and now, it would appear that it occurs 30 minutes after the ligand is internalised. So 
could the ligand be entering the cell via receptor-mediated endocytosis, making its way 
along the endocytic pathway to the lysosomal enzymes and subsequently degraded and 
expelled, resulting in a reduced amount of ligand appearing intracellularly?
In an attempt to answer this question, the inclusion of enzymes known to inhibit certain 
classes of lysosomal enzymes were introduced into the cell system. About fifty lysosomal 
enzymes are known and their properties are reviewed by Barrett (1984). There are 
basically four pathways involved in lysosomal metabolism: proteolytic, glycanolytic, 
nuclease and lipolytic pathways. The proteolytic and nuclease pathways start with 
enzymes specialised for action on the inner regions of the intact polymers that are their 
substrates, the endopeptidases and endonucleases, respectively. Early evidence of the role 
of lysosomes in the intracellular degradation of endogenous proteins came from the work 
of Dean, R.T. (1977), with liver cells, in which it was shown that pepstatin partially
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inhibited the process. Leupeptin, a second protease inhibitor, is known to inhibit 
cysteine/serine proteases (Barrett, A J.; 1984).
With this knowledge, an attempt was made to observe if by adding pepstatin A or 
leupeptin to the experimental set-up, inhibition of degradation occurred. For both 
inhibitors, no observable increase in the intracellular 125I activity, which would reflect an 
inhibition of protease degradation, was found to occur. It would appear then that the 
protease enzymes present in the lysosome are not responsible for the degradation of the 
ligand. However, it must be emphasised that a comparatively low concentration of the 
inhibitors were employed (lOjigmH). Harford & Klausner (1987), for example in their 
attempt at studying receptor-mediated endocytosis in rat hepatocytes, treated cells with a 
10-fold more concentrated solution of leupeptin. Using lOOpgml' 1 of leupeptin, they 
found an accumulation of radioactivity in the lysosomal region of the percoll gradient they 
employed in subcellular fractionation of their cells (Harford, J. & Klausner, R.D.; 1987). 
Unfortunately there was no time to repeat these experiments using a 10-fold increase in 
the protease inhibitors chosen here. So, although, the results obtained in this study suggest 
that the protease enzymes are not responsible for the degradation of the internalised [1 2 5I- 
Tyr2 -Nle4 ,D-Phe7] a-MSH, in no way can this be accepted as the whole story.
Overall, as far as internalisation of the a-MSH analogue, [Nle4 ,D-Phe7 ]a-MSH is 
concerned, and, what happens to it once it has been internalised, the following facts have 
been determined:-
1. Internalisation of [1 2 5I-Tyr2 -Nle4 ,D-Phe7 ]a-MSH does occur.
2. Maximum internalisation is seen to occur at 30 minutes, followed by a gradual
decrease.
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3. The cause for the decrease in acid-resistant 125I activity has been shown to be linked 
with degradation of the ligand by inclusion of NH4 CI into the cell system.
It must be further noted that an essential area to be examined as confirmation of these 
observations, is the identification of the degraded ligand. Although not reported here, an 
attempt at proving that degradation was happening was tested using the familiar 
trichloroacetic acid method. No success was achieved however. This was mainly due to 
the fact that the intact [1 2 5I-Tyr2 -Nle4 ,D-Phe7 ]a-MSH, itself, was not precipitated by 
10% TCA. Therefore, this method of confirming degradation could not be used. In 
addition, a very naive approach incorporating HPLC techniques as examined. 
Unfortunately, the background 125I activity present on the HPLC equipment available for 
analysis of the test samples was much greater than the level of 125I activity within the cells 
or incubation media from the cells. In respect of these initial attempts at identifying 
degradation products of [1 2 5I-Tyr2 -Nle4 ,D-Phe7] a-MSH, much scope is available for an 
independent study. One pathway possibly worth examination is one already started by 
Panasci, et al (1987). They set up a study on the metabolic fate of tritriated Ac-[Nle4 ,D- 
Phe7 ]a-MSH4 .1 1NH4  with the FI variant of B16 melanoma cells. A 30cm Sephadex G-10 
column was used to try and separate the various degraded products, and some success 
was achieved (Panasci, L.C. et al; 1987).
It is suffice to say that although the study reported here does prove the internalisation of 
[l2 5l-Tyr2 -Nle4 ,D-Phe7 ]a-MSH, and there is strong evidence for degradation occurring, 
much work involving degradation must be carried out to confirm, without any doubt, that 
this is the reason for the decrease in acid-resistant 125I activity in the B16 melanoma cells 
after 30 minutes incubation at 37 °C.
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In parallel to the cell binding experiments just described, a series of subcellular 
fractionation experiments were designed. The aim of such were to follow the ligand once 
it had been internalised and hopefully monitor its fate; and in addition, if possible to 
quantify the amount of ligand intracellularly located. Even as early as 1971, DeDuve made 
detailed studies on the fractionation of tissues and cells. As far as the study here is 
concerned, the major compartments under scrutiny are the plasma membrane and the 
lysosome. The former, because, the plasma membrane is the site where the a-MSH 
receptor is located, and so 125I activity associated with this area is extracellularly bound to 
the cells. The lysosome, is of great interest in respect of results obtained in the cell binding 
experiments in which degradation was strongly implied. Since the lysosome is otherwise 
referred to as the "degradative component of the cell", then it is assumed that this is the 
compartment where the ligand travels to along the endocytic pathway, prior to 
degradation.
In order to characterise the components under study, enzyme marker assays were 
introduced. The suitability of a particular enzyme for a cell type varies from cell to cell. 
During the course of the experiments, it was discovered that 5-nucleotidase, a plasma 
membrane marker and p-glucuoronidase, a lysosomal marker were not sensitive enough to 
be measured for B16 melanoma cells. Instead alkaline phosphodiesterase I and p- 
hexosaminidase (plasma membrane and lysosomal markers respectively), were chosen.
Due to the fact that very little work has been documented up to date regarding the 
subcellular fractionation of B16 melanoma cells, a lot of "trial and error" was invovled. To 
begin with, the initial step in the whole process of subcellular fractionation is cell lysing, 
also known as homogenisation. In effect this is probably the most crucial step in the 
procedure mainly because the major aim for this study was to be able to isolate the plasma 
membrane and lysosomal components. An ideal homogenisation technique involves one
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which separates the components so as not to disrupt internal component membranes. The 
two tools used were the needle and syringe method and the dounce homogeniser method- 
both depend on the force exerted by the operator. Although, for the method chosen, the 
needle and syringe method, it was standardised as far as possible in the fact that the 
syringe was pushed in 1 second each time. The cell lysis achieved was monitored by 
visualising the cells by use of the light microscope and incorporating a trypan blue dye 
which gives broken/disrupted cells a blue appearance. Each time, 90% lysis was used as 
the standard optimum for the cell lysis.
After homogenisation, the cells were subjected to a centrifugation step on a linear sucrose 
gradient in an attempt to separate the cellular components at different densities of sucrose. 
Fractionation of the density gradient was then carried out, and the fractions obtained 
analysed by enzyme marker assays to locate the position of the plasma membrane and 
lysosome components. In theory, if a method whereby efficient separation of these 
components can be achieved, then when a radioligand is added to the system, the resulting 
fractions can be monitored for 125I activity and so the location of the iodinated ligand can 
be found.
Unfortunately this whole technique is not as simple as it seems. More often than not, 
satisfactory separation of the two components of interest was obtained. On the other hand, 
however, the plasma membrane component was not restricted to densities lower than for 
the lysosome. In effect, it was often observed in fractions normally associated with the 
lysosome. Due to this problem, it was obvious from early on that no quantitative 
measurements could be made. Another reason for this was that the entire procedure 
involves a large loss of radioactivity throughout the various stages of the experiment.
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Even though a "perfect" system had not been developed as far as quantitative 
measurements were concerned, the system was adequate to determine the intracellular 
location of the [1 2 5I-Tyr2 ,Nle4 ,D-Phe7] a-MSH. Initial experiments which involved 
binding of [1 2 5I-Tyr2 ,Nle4 ,D-Phe7] a-MSH to the cells were such that it could be clearly 
seen if internalisation at 37°C could be distinctly observed compared to no internalisation 
at 4°C. Indeed, this was the case and for the cells incubated at 37°C, a large amount of 
125I activity was associated with densities reflecting intracellular compartments. Acid- 
resistant 125I activity contained a peak of activity between fractions 16 and 2 2  (densities 
1.16 to 1.18gcm"3); a similar peak was not found for the equivalent 4°C experiment
Since it appeared possible to separate the internalised from surface-bound 125I activity 
using cell fractionation, a series of timecourse experiments were designed. As for cell 
binding experiments, the ligand was allowed to bind to the cells for 2 hours at 4°C, at 
which point unbound radioligand was removed and the surface-bound ligand was 
permitted to enter the cells by incubation at 37°C. In general, the results obtained from 
these studies did show from the acid-washed data a gradual increase in 125I activity 
around fractions 16 to 18 at 15 minutes. This was also apparent at the 30 minute 
timepoint, however, at 60 minutes 125I activity present was not only very low, but it was 
spread widely over the gradient. At the first timepoint no internalised ligand is observed in 
the higher density lysosomal fractions due to surface binding occurring at 4°C. As the 
temperature was raised to 37°C, a gradual increase in 125I activity could be seen in the 
higher density area corresponding to the lysosomal compartments. By 60 minutes, very 
little 125I activity was associated with the cells at all. This could reflect degradation of the 
ligand and hence the disappearance of any radioactivity associated with the cells.
In view of the results obtained above, a parallel experiment was carried out, but, in the 
presence of 20mM NH4 CI. Not surprisingly, this had the effect of maintaining a raised
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level of 125I activity within the cells as long as 60 minutes. Moreover, there was a peak of 
radioactivity present in the fractions relating to the lysosomal compartment. So it has been 
shown that the ligand binds to the receptor and moves inwards along the endocytic 
pathway to the lysosome where it remains if no degradation can occur due to inhibition of 
the degradative enzymes.
Again it must be emphasised that without an assay to identify degradative products for the 
[l25i_Tyr2,Nle4JD-Phe7]a-MSH analogue, complete confirmation that the decrease in 125I 
activity is associated with degradation. These cell fractionation studies do further imply 
such a phenomenon however and coincide with results obtained with cell binding 
experiments.
Therefore, as far as the sucrose gradient fractionation studies are concerned, at least one 
of the questions being challenged was answered somewhat. Unfortunately, until a more 
efficient and more consistent method of cell homogenisation is available quantitative 
analysis of the 125I activity cannot be determined. Alternative gradient materials or 
centrifugation techniques are also a consideration to be kept in mind.
The final area of study was to consider the size of the ligand and observe its effect on the 
internalisation rate. In practice, the peptide will be the carrier, and a drug of higher 
molecular weight will be attached to the ligand. Therefore, even if the peptide [Nle4 ,D- 
Phe7] a-MSH itself can efficiently enter the cells it must be shown that when molecules of 
high molecular weight and larger size are attached to it, efficient internalisation still
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occurs. What would be the advantage of having a carrier which transports a drug to the 
required site of action, but no mechanism of getting it inside the cell exists?
Therefore, the [Nle4,D-Phe7] a-MSH was in effect increased in size by the addition of 
biotin, and then streptavidin to the biotinylated peptide. For the former ligand, Na-biotin- 
[Nle4,D-Phe7] a-MSH, little difference was observed in the internalisation of the ligand. 
On the other hand however, the streptavidin- biotin-[Nle4,D-Phe7]a-MSH did not enter 
the cell as quickly. At the normal 90 minute period of the experiment, the 125I activity was 
still shown to increasing. When the experiment was extended to 240 minutes, it was 
apparent that all the streptavidin-biotin-[Nle4,D-Phe7]a-MSH had entered the cells by 90 
minutes and then a gradual decrease was observed. The major reason for the slowness of 
the streptavidin-biotin-[Nle4,D-Phe7] a-MSH uptake was probably due to the size of the 
streptavidin moiety. It is possible that it restricts the binding of the [Nle4,D-Phe7]a-MSH 
to the a-MSH receptor, hence, decreasing the efficiency of the entire system. Although 
only one set of data for this was available, it must be considered when adding drug 
molecules to the peptide that a decrease in rate of internalisation of the ligand-drug 
complex may occur.
Overall, the following points have been answered to some extent: -
1. It was confirmed that [125I-Tyr2,Nle4,D-Phe7]a-MSH was bound to the a-MSH 
receptor on the cell surface and was subsequently internalised.
2. There was evidence to suggest from sucrose gradient fractionation studies that once
within the cells, the ligand made its way to the lysosome.
3. Once the ligand reaches the lysosome, there is strong evidence from inclusion of
ammonium chloride that degradation of the ligand occurs in the lysosome.
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4. Inclusion of some protease inhibitors, leupeptin and pepstatin A, no inhibition of
degradation was observed.
5. By adding larger moieties to the [125I-Tyr2,Nle4,D-Phee7]a-MSH, the rate of 
internalisation was reduced.
In addition to the above areas where certain areas have been answered satisfactorily the 
following issues still need further confirmation:
1. Degradation does occur- it is necessary to develop an assay to isolate and recognise
the degradative products
2. Further work on the subcellular fractionation - particularly the method of 
homogenising the B16 melanoma cells
3. Repeat of some of the protease enzyme inhibition enzyme work using a 10-fold
higher concentration of the enzyme inhibitors
4. Further studies on addition of drugs to the Ac[Nle4,D-Phe7] a-MSH ligand, and 
monitoring their internalisation rates
5. All this work has been carried out on B16 murine melanoma cells, parallel work on
human melanoma cell lines need to be studied, followed by in vivo work
Although, it is apparent that there is still much scope of study left to do regarding the drug 
targeting of a-MSH analogues to melanoma cells, it is hoped that the work included in 
this thesis will be of some use to future workers in this area of research. In addition, it is 
necessary to bear in mind the similarity of MSH to other peptides, such as, ACTH and so 
care must be taken owing to the possibility of cross-recognition of the analogues. 
Furthermore, it is of the utmost necessity to establish if drug-analogue conjugates are 
capable of entering the cell and the drug can be released in a toxic form.
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In conclusion, however, the specificity of peptides for their receptors indicate them to be 
extremely useful tools in selective drug delivery. Proof of their internalisation is also a step 
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Density, Refractive Index and Concentration Data for Sucrose at 20°C, 










0.9982 1.3330 0 - -
1.0021 1.3344 1 10 0.029
1.0060 1.3359 2 20.1 0.059
1.0099 1.3374 3 30.3 0.089
1.0139 1.3388 4 40.6 0.119
1.0179 1.3403 5 50.9 0.149
1.0219 1.3418 6 61.3 0.179
1.0259 1.3433 7 71.8 0.210
1.0299 1.3448 8 82.4 0.211
1.0340 1.3464 9 93.1 0.272
1.0381 1.3479 10 103.8 0.303
1.0423 1.3494 11 114.7 0.335
1.0465 1.3510 12 125.6 0.367
1.0507 1.3526 13 136.6 0.399
1.0549 1.3541 14 147.7 0.431
1.0592 1.3557 15 158.9 0.464
1.0635 1.3573 16 170.2 0.497
1.0678 1.3590 17 181.5 0.530
1.0721 1.3606 18 193.0 0.564
1.0765 1.3622 19 204.5 0.597
1.0810 1.3639 20 216.2 0.632
1.0854 1.3655 21 227.9 0.666
1.0899 1.3672 22 239.8 0.701
1.0944 1.3689 23 251.7 0.735











1.1036 1.3723 25 275.9 0.806
1.1082 1.3740 26 288.1 0.842
1.1128 1.3758 27 300.5 0.878
1.1175 1.3775 28 312.9 0.914
1 . 1 2 2 2 1.3793 29 325.4 0.951
1.1270 1.3811 30 338.1 0.988
1.1318 1.3829 31 350.9 1.025
1.1366 1.3847 32 363.7 1.063
1.1415 1.3865 33 376.7 1 . 1 0 0
1.1463 1.3883 34 389.7 1.138
1.1513 1.3902 35 403.0 1.177
1.1562 1.3920 36 416.2 1.216
1.1612 1.3939 37 429.6 1.255
1.1663 1.3958 38 443.2 1.295
1.1713 1.3978 39 456.8 1.334
1.1764 1.3997 40 470.6 1.375
1.1816 1.4016 41 484.5 1.415
1.1868 1.4036 42 498.5 1.456
1.1920 1.4056 43 512.6 1.498
1.1972 1.4076 44 526.8 1.539
1.2025 1.4096 45 541.1 1.581
1.2079 1.4117 46 555.6 1.623
1.2132 1.4137 47 570.2 1 . 6 6 6
1.2186 1.4158 48 584.9 1.709
1.2241 1.4179 49 599.8 1.752
1.2296 1.4200 50 614.8 1.796
1.2351 1.4221 51 629.9 1.840
1.2406 1.4242 52 645.1 1.885
1.2462 1.4264 53 660.5 1.930











1.2575 1.4307 55 691.6 2 . 0 2 0
1.2632 1.4329 56 707.4 2.067
1.2690 1.4351 57 723.3 2.113
1.2748 1.4373 58 739.4 2.160
1.2806 1.4396 59 755.6 2.207
1.2865 1.4418 60 771.9 2.255
1.2924 1.4441 61 788.3 2.303
1.2983 1.4464 62 788.3 2.351
1.3043 1.4486 63 804.9 2.401
1.3103 1.4509 64 821.7 2.450
1.3163 1.4532 65 855.6 2.500
1.3224 1.4558 6 6 872.8 2.550


































































Sucrose Dilution Chart For M olar Concentrations
Sucrose Concentration (M )
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APPENDIX B
EXPERIMENTAL DATA FOR CHAPTER 3
B1 Binding and Internalisation of O.lnM [1 2 5 I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH with B16 











CPM ± CPM ± CPM ± CPM ±
15 2000 107 326 7 1674 107 165 43
30 2804 285 418 27 2386 286 214 35
60 4474 306 420 53 4054 310 228 33
90 5606 529 507 48 5099 531 410 112
120 6468 621 666 86 5802 626 437 67
240 10614 631 1077 90 9537 637 713 100
B2 Binding and Intemalisaton of O.lnM [1 2 5I-Tyr2 ,Nle4 ,D-PHE7 ]a-MSH with 











CPM ± CPM ± CPM ± CPM ±
15 670 66 521 68 149 94 219 44
30 823 97 473 70 350 119 210 14
60 1211 149 737 137 474 202 221 74
90 1682 130 1002 139 680 190 232 19
120 1753 136 952 166 801 214 269 30
240 2278 294 1243 104 1035 311 404 29
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B3 Binding and Internalisation of O.lnM [1 2 5 I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH with B16
Melanoma Cells at 37°C in the Absence of 20mM NH4 CI with Time in a HEPES











CPM ± CPM ± CPM ± CPM ±
15 3760 370 312 58 3448 374 435 23
30 8940 505 366 70 8574 509 2857 265
60 13202 1077 522 69 12680 1079 5201 62
90 12946 452 461 36 12485 453 5267 293
120 11091 565 511 42 10581 566 4681 638
240 6078 196 836 52 5242 202 3790 85
B4 Binding and Internalisation of O.lnM [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH with B16 
Melanoma Cells at 37°C in the Absence of 20mM NH4 CI with Time in a HEPES 











CPM ± CPM ± CPM ± CPM ±
15 2838 346 261 42 2577 348 310 24
30 5580 608 369 22 5211 608 1101 111
60 7720 345 330 15 7390 345 2894 183
90 7050 322 396 66 6654 328 2666 174
120 6538 240 374 39 6164 243 2552 131
240 4426 546 369 30 4057 546 2414 87
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B5 Binding and Internalisation of O.lnM [ 1 2 5 I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH with B16
Melanoma Cells at 37°C in the Presence of 20mM NH4 CI with Time in a HEPES











CPM ± CPM ± CPM ± CPM ±
15 5179 236 383 31 4796 238 872 50
30 9491 388 283 30 9208 389 3553 68
60 14109 80 397 270 13712 84 7965 313
90 19726 674 413 22 19313 674 13300 1144
120 21862 2074 544 61 21318 2074 15973 1285
240 28917 1568 866 39 28051 1568 25868 700
B6  Binding and Internalisation of O.lnM [1 2 5I-Tyr2 ,Nle4 ,D-Phe7]a-MSH with B16 
Melanoma Cells at 37°C in the Presence of 20mM NH4 CI with Time in a HEPES 











CPM ± CPM ± CPM ± CPM ±
15 5966 438 306 28 5660 438 793 83
30 12132 1056 267 19 11865 1056 4073 491
60 20740 708 407 21 20333 708 11282 470
90 28346 1834 402 32 27944 1834 18840 1343
120 33135 3423 563 26 32572 3423 23308 1391
240 47362 3467 959 32 46403 3467 38511 1077
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B7 Internalisation of O.lnM [1 2 5 I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH at 37°C after binding for












CPM ± CPM ± CPM ± CPM ±
0 4408 73 312 39 4096 83 25 39
5 3436 358 95 53 3341 361 560 57
10 2785 323 73 20 2712 323 791 114
20 3014 270 58 12 2956 270 1055 40
30 2975 76 59 9 2916 76 1225 21
45 2465 147 52 25 2413 149 910 70
90 1569 230 38 21 1531 231 391 66
B8  Internalisation of O.lnM [1 2 5I-Tyr2 ,Nle4 J)-Phe7 ]a-MSH at 37°C after binding for 












CPM ± CPM ± CPM ± CPM ±
0 6662 391 477 70 6185 397 718 258
5 6184 163 142 35 6042 166 920 238
10 6039 384 96 18 5943 384 1228 166
20 5186 348 156 94 5030 360 1431 158
30 5197 402 89 15 5108 402 2387 170
45 4329 339 109 53 4220 343 2186 145
90 2101 555 87 37 2014 556 973 301
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B9 Internalisation of O.lnM [1 2 5 I-Tyr2 ,Nle4 JD-Phe7 ]a-MSH at 37°C after binding for












CPM ± CPM ± CPM ± CPM ±
0 2513 113 328 7 2185 113 283 42
5 1994 248 157 11 1837 248 242 21
10 1614 209 141 31 1473 211 357 41
20 1545 139 114 34 1431 143 469 36
30 1974 144 121 27 1853 146 693 108
45 1602 108 105 21 1497 110 875 84
90 1688 246 76 4 1612 246 1585 151
BIO Internalisation of O.lnM [1 2 5I-Tyr2 ,Nle4 JD-Phe7 ]a-MSH at 37°C after binding 












CPM ± CPM ± CPM ± CPM ±
0 2395 179 706 5 1689 179 399 71
5 1550 107 271 8 1279 107 298 105
10 1333 155 221 19 1112 156 302 26
20 1272 157 178 15 1094 158 328 16
30 1131 46 111 10 1020 47 471 18
45 982 85 83 15 899 86 587 5
90 950 57 64 15 886 59 932 24
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B ll  Internalisation of O.lnM [1 2 5 I-Tyr2 ,Nle4 JD-Phe7 ]a-MSH at 37°C after binding












CPM ± CPM ± CPM ± CPM ±
0 3220 162 91 61 3129 173 109 10
5 2603 185 89 18 2514 185 253 26
10 2443 230 44 12 2399 230 430 39
20 2692 108 63 3 2629 108 854 46
30 2080 169 32 23 2048 170 1213 53
45 2008 60 37 8 1971 60 1019 58
90 879 230 21 13 858 230 435 64
B12 Internalisation of O.lnM [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH at 37°C after binding 












CPM ± CPM ± CPM ± CPM ±
0 1389 61 347 65 1263 72 121 10
5 1263 72 109 7 1154 72 153 7
10 1460 201 46 26 1414 202 247 39
20 1250 65 63 15 1187 66 438 36
30 1140 89 35 25 1105 92 538 68
45 903 69 42 2 861 69 386 23
90 400 34 21 14 379 36 230 27
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B13 Internalisation of O.lnM [1 2 5l-Tyr2 ,Nle4 JD-Phe7 ]a-MSH at 37°C after binding












CPM ± CPM ± CPM ± CPM ±
0 3921 658 144 17 3777 658 148 13
5 3254 285 102 20 3152 285 437 36
10 3284 257 113 38 3171 257 592 38
20 3042 249 81 18 2961 249 1118 69
30 3119 18 31 7 3088 19 1432 83
45 2488 141 68 18 2420 142 1203 152
90 1147 140 27 14 1120 140 670 22
B14 Internalisation of O.lnM [1 2 5I-Tyr2 ,Nle4 JD-Phe7 ]a-MSH at 37°C after binding 












CPM ± CPM ± CPM ± CPM ±
0 2310 64 658 61 1652 88 233 21
5 1272 135 123 9 1149 135 193 21
10 1644 275 104 19 1540 275 336 29
20 1534 75 102 25 1432 79 748 61
30 1272 24 71 25 1201 34 637 49
45 810 191 56 22 754 192 410 24
90 481 103 51 24 430 105 291 54
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B15 Internalisation of O.lnM [1 2 5 I-Tyr2 ,Nle4 JD-Phe7 ]a-MSH at 37°C after binding












CPM ± CPM ± CPM ± CPM ±
0 3440 219 310 45 3130 223 128 11
5 2795 251 86 8 2709 251 254 16
10 2909 359 73 11 2836 359 379 65
20 2513 148 63 16 2450 148 618 70
30 1969 68 10 5 1959 68 941 43
45 1947 344 54 23 1893 344 890 75
90 1259 383 36 7 1223 383 501 46
B16 Internalisation of O.lnM [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH at 37°C after binding 












CPM ± CPM ± CPM ± CPM ±
0 2974 128 677 151 2297 197 242 20
5 1562 95 160 73 1402 119 238 29
10 1386 184 172 13 1214 184 326 161
20 986 67 61 13 925 68 495 61
30 1066 84 26 11 1040 84 529 29
45 655 86 60 8 595 86 409 19
90 336 58 17 5 319 58 210 30
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B17 Internalisation of O.lnM [1 2 5 I-Tyr2 ,Nle4 JD-Phe7 ]a-MSH at 37°C after binding












CPM ± CPM ± CPM ± CPM ±
0 3123 369 324 18 2799 369 151 21
5 2795 230 84 19 2711 230 379 92
10 2675 211 88 8 2587 211 550 27
20 2375 255 57 9 2318 255 713 20
30 1921 210 21 16 1900 210 933 37
45 1672 235 62 34 1610 237 809 115
90 1056 364 42 39 1014 366 548 135
B18 Internalisation of O.lnM [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH at 37°C after binding 












CPM ± CPM ± CPM ± CPM ±
0 2427 121 661 49 1766 130 263 37
5 1611 77 114 17 1497 78 199 27
10 1561 456 143 46 1418 162 312 44
20 1529 78 130 19 1399 80 676 43
30 1197 44 42 24 1155 50 606 31
45 1047 31 108 24 939 39 586 100
90 404 82 39 18 365 83 281 46
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APPENDIX C
EXPERIMENTAL DATA FOR CHAPTER 4
C l Density of fractionated linear sucrose gradients against fraction number



























C2 p-Hexosaminidase activity present in the sucrose fractions of the densities shown 
(Note, the enzyme assay was performed on alternate sucrose fractions due to the 
amount of sample there was available)





1 0 1.108 0.064




2 0 1.171 0.135
2 2 1.187 0.801
24 1.197 0.135
C3 Alkaline Phosphodiesterase I activity present in the sucrose fractions of the 
densities shown
(Note, the enzyme assay was performed on alternate sucrose fractions due to the 
amount of sample there was available)





1 0 1.103 0.228




2 0 1.161 0.346
2 2 1.176 0.285
24 1.192 0.250
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C4 125I Activity associated with each sucrose fraction for cell incubated for 2 hours at










1 482 216 127
2 470 204 126
3 403 179 90
4 284 82 60
5 191 86 33
6 162 52 29
7 138 28 13
8 125 26 18
9 99 11 9
10 149 4 4
11 141 11 13
12 136 11 14
13 137 10 9
14 130 10 10
15 144 8 24
16 138 6 23
17 160 15 18
18 163 15 21
19 185 11 24
20 247 19 15
21 266 28 15
22 262 17 11
23 232 15 8
24 220 15 7
25 226 13 6
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C5 125I Activity associated with each sucrose fraction for cell incubated for 2 hours at
4°C with O.lnM [1 2 5 I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH followed by 30 minutes incubation at









1 729 143 327
2 677 135 283
3 552 97 215
4 463 59 174
5 437 42 1 1 0
6 511 24 81
7 690 14 73
8 785 19 75
9 829 1 2 103
1 0 843 6 119
1 1 764 1 0 129
1 2 762 9 142
13 723 6 170
14 733 13 2 0 0
15 804 15 320
16 943 15 431
17 1317 17 636
18 1870 2 2 672
19 2090 26 548
2 0 1116 27 697
2 1 1246 35 331
2 2 1169 23 277
23 1 0 1 2 17 98
24 771 1 0 1 0 2
25 308 15 79
183
C6  125I activity associated with each sucrose fraction for cells incubated for 2  hours at
4°C with O.lnM [1 2 5 I-Tyr2 ,Nle4 JD-Phe7 ]a-MSH followed by the relevant times
incubation at 37°C prior to homogenisation and fractionation.
FRACTION
NUMBER
ONLY AT 4°C AFTER 15 MINUTES AT 37°C
TOTAL ACID TOTAL ACID
BINDING WASHED BINDING WASHED
(CPM) (CPM) (CPM) (CPM)
1 483 6 147 45
2 471 15 131 46
3 419 2 140 37
4 363 32 153 19
5 278 2 0 1 1 2 14
6 2 0 1 8 93 6
7 142 5 1 1 2 7
8 136 0 117 8
9 124 0 139 14
1 0 148 8 128 27
1 1 127 6 154 30
1 2 128 9 142 2 0
13 141 2 0 138 27
14 147 7 144 15
15 131 1 1 167 26
16 169 0 195 30
17 186 7 2 2 2 45
18 242 15 241 69
19 325 2 0 240 50
2 0 358 26 165 41
2 1 278 2 0 124 30
2 2 196 1 90 9
23 204 17 59 1
24 181 4 39 13
25 144 0 54 2 0
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C6  (continued) 125I activity associated with each sucrose fraction for cells incubated
for 2 hours at 4°C with O.lnM [1 2 I^-Tyr2 ,Nle4 JD-Phe7 ]a-MSH followed by the
relevant times incubation at 37°C prior to homogenisation and fractionation.
FRACTION
NUMBER
AFTER 30 MINUTES AT 37°C AFTER 60 MINUTES AT 37°C
TOTAL ACID TOTAL ACID
BINDING WASHED BINDING WASHED
(CPM) (CPM) (CPM) (CPM)
1 81 36 39 15
2 90 16 33 0
3 63 13 15 8
4 72 2 13 1 2
5 57 1 16 17
6 55 9 28 23
7 81 28 40 19
8 58 2 1 32 15
9 80 40 25 13
1 0 90 30 19 0
1 1 82 35 6 0
1 2 84 32 18 0
13 76 36 35 6
14 85 54 2 2 2 1
15 1 1 1 52 43 2 0
16 94 80 35 8
17 150 75 26 1 1
18 303 46 25 6
19 103 42 18 0
2 0 75 15 17 16
2 1 41 1 0 18 7
2 2 30 15 2 0 18
23 44 13 23 19
24 50 39 24 8
25 27 19 8 2
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C7 125I activity associated with each sucrose fraction for cells incubated for 2 hours at 
4°C with O.lnM [1 2 5I-Tyr2 ,Nle4 J)-Phe7 ]a-MSH followed by the relevant times 




ONLY AT 4°C AFTER 15 MINUTES AT 37°C
TOTAL ACID TOTAL ACID
BINDING WASHED BINDING WASHED
(CPM) (CPM) (CPM) (CPM)
1 491 37 439 37
2 447 43 384 43
3 403 44 364 44
4 643 39 292 39
5 466 35 228 35
6 328 33 2 0 0 33
7 274 1 2 214 14
8 229 30 166 1 2
9 2 2 0 32 190 43
1 0 183 45 203 43
1 1 186 44 196 45
1 2 196 44 182 52
13 2 1 2 47 176 44
14 198 44 203 47
15 164 49 224 44
16 242 35 182 52
17 250 34 176 44
18 437 44 203 47
19 506 50 224 44
2 0 460 27 272 49
2 1 398 17 355 73
2 2 377 1 2 412 69
23 406 7 443 8 8
24 525 18 559 198
25 343 14 283 55
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C7 (continued) 125I activity associated with each sucrose fraction for cells incubated 
for 2 hours at 4°C with O.lnM [1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ](X-MSH followed by the 




AFTER 30 MINUTES AT 37°C AFTER 60 MINUTES AT 37°C
TOTAL ACID TOTAL ACID
BINING WASHED BINDING WASHED
(CPM) (CPM) (CPM) (CPM)
1 287 216 97 337
2 254 184 65 191
3 227 119 52 115
4 186 8 8 27 91
5 172 35 43 77
6 182 27 42 6 8
7 183 57 52 48
8 213 55 51 29
9 180 60 45 24
1 0 194 75 53 23
1 1 162 44 40 27
1 2 157 79 53 25
13 148 71 60 42
14 193 140 96 6 8
15 260 158 96 82
16 321 71 160 106
17 477 140 269 154
18 477 158 452 156
19 497 228 653 258
2 0 381 264 549 348
2 1 293 284 419 376
2 2 227 275 328 311
23 186 247 266 189
24 234 203 284 156
25 277 171 194 125
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APPENDIX D
EXPERIMENTAL DATA FOR CHAPTER 5
D1 Internalisation of Biotin-[1 2 5I-Tyr2 ,Nle4 JD-Phe7 ]a-MSH at 37°C after binding for 












CPM ± CPM ± CPM ± CPM ±
0 4692 313 1128 43 3563 315 190 36
5 3248 352 178 28 3070 353 594 57
10 2882 469 129 26 2752 469 675 76
20 2229 235 107 29 2122 236 668 32
30 1272 212 101 39 1171 215 549 102
45 1330 164 58 19 1272 165 470 65
90 993 198 53 22 940 199 447 41
D2 Internalisation of Biotin-[1 2 5I-Tyr2 ,Nle4 JD-Phe7 ]a-MSH at 37°C after binding for 












CPM ± CPM ± CPM ± CPM ±
0 1789 282 1356 55 433 287 15 30
5 1241 76 862 56 379 94 341 64
10 1121 111 766 93 355 144 404 987
20 867 77 558 14 309 78 387 10
30 534 73 209 28 325 78 30 54
45 479 80 140 17 335 81 64 37
90 384 29 84 3 300 29 347 17
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D3 Internalisation of Biotin-[1 2 5 I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH at 37°C after binding for












CPM ± CPM ± CPM ± CPM ±
0 3672 113 448 17 3225 114 30 18
5 2577 211 123 16 2454 211 233 20
10 2321 213 88 16 2234 213 368 27
20 2467 183 111 11 2356 183 552 50
30 2261 58 185 100 2076 115 596 35
45 2252 98 64 15 2192 99 786 97
90 2163 87 40 5 2132 87 1422 46
D4 Internalisation of Biotin-[1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH at 37°C after binding for 












CPM ± CPM ± CPM ± CPM ±
0 5585 371 1120 106 4465 385 200 50
5 4194 129 250 42 3944 135 556 47
10 4044 216 190 19 3854 216 676 7
20 3674 138 158 14 3516 138 850 47
30 3483 79 126 17 3357 80 1062 92
45 339 178 111 7 3228 178 1503 47
90 3268 206 99 28 3169 207 2296 110
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D5 Internalisation of Streptavidin-Biotin-[ 1 2 5 I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH at 37°C
after binding for 2 hours at 4°C into B16 Melanoma Cells with time (n=4) in the











CPM ± CPM ± CPM ± CPM ±
0 1786 204 374 14 1412 204 80 18
5 1301 319 139 29 1162 320 289 37
10 890 112 127 14 763 113 347 51
20 802 76 106 9 696 76 481 26
30 931 12 92 20 839 23 505 24
45 736 115 159 42 577 122 509 12
90 349 80 72 12 277 81 695 12
D6  Internalisation of Streptavidin-Biotin-[1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH at 37°C 
after binding for 2 hours at 4°C into B16 Melanoma Cells with time (n=4) in the 











CPM ± CPM ± CPM ± CPM ±
0 2267 127 556 21 1711 128 77 17
5 1589 100 121 15 1468 101 266 25
10 1345 69 88 23 1257 73 301 7
20 1316 45 57 13 1259 46 512 48
30 1117 158 75 16 1042 158 536 37
45 1036 71 68 14 968 72 645 60
90 438 50 19 19 419 53 739 154
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D7 Internalisation of Streptavidin-Biotin-[125I-Tyr2,Nle4JD-Phe7]a-MSH at 37°C












CPM ± CPM ± CPM ± CPM ±
0 1777 161 833 74 944 177 89 38
5 833 42 118 16 715 44 201 36
10 726 99 94 15 632 100 267 35
20 537 93 55 11 482 93 194 97
30 414 63 31 15 383 64 276 41
45 514 142 23 13 491 142 444 32
90 335 46 3 3 332 46 601 60
240 169 30 14 10 155 31 434 11
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D8  Internalisation of Streptavidin-Biotin-[125I-Tyr2,Nle4J)-Phe7]a-MSH at 37°C












CPM ± CPM ± CPM ± CPM ±
0 2256 187 573 22 1683 188 44 10
5 1619 54 150 7 1469 54 415 45
10 1406 33 96 8 1310 33 481 26
20 1347 208 80 11 1267 208 582 36
30 1157 131 94 20 1063 132 619 59
45 1000 23 47 24 953 33 658 49
90 1047 94 24 5 1023 94 830 80
D9 Internalisation of Streptavidin-Biotin-[1 2 5I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH at 37°C 
after binding for 2 hours at 4°C into B16 Melanoma Cells with time (n=4) in the 











CPM ± CPM ± CPM ± CPM ±
0 1822 33 411 34 1411 47 58 35
5 1358 72 225 33 1134 79 375 44
10 1147 146 187 20 960 147 313 40
20 1068 72 146 17 922 73 497 61
30 1127 68 133 13 994 69 582 33
45 933 90 133 17 800 91 618 30
90 936 37 102 15 834 39 871 95
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DIO Internalisation of Streptavidin-Biotin-[1 2 5 I-Tyr2 ,Nle4 ,D-Phe7 ]a-MSH at 37°C
after binding for 2 hours at 4°C into B16 Melanoma Cells with time (n=4) in the











CPM ± CPM ± CPM ± CPM ±
0 1822 251 586 13 1236 251 328 39
5 1273 131 186 30 1087 134 463 47
10 981 43 111 11 870 44 511 30
20 827 67 77 11 750 67 563 113
30 751 162 45 29 706 164 585 44
45 824 125 54 8 770 125 605 61
90 951 31 26 19 925 36 849 80
240 844 109 72 28 772 112 914 90
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